# WEST Search History

DATE: Wednesday, May 21, 2003

| Set Name side by side | Query | Hit Count | Set Name result set |
|---|---|---|---|
| *DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ* | | | |
| L3 | L2 and transport systems | 58 | L3 |
| L2 | L1 and cell membrane | 569 | L2 |
| L1 | protein transport | 1320 | L1 |

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 14:51:25 ON 21 MAY 2003)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 14:51:41 ON 21 MAY 2003

| | | |
|---|---|---|
| L1 | 31969 | S TRANSPORT SYSTEMS |
| L2 | 314056 | S (NONSPECIFIC OR NON-SPECIFIC) |
| L3 | 572 | S L1 AND L2 |
| L4 | 425 | DUP REM L3 (147 DUPLICATES REMOVED) |
| L5 | 16 | S L4 AND PERIPLASM |
| L6 | 138 | S L4 AND (BACTERIA) |
| L7 | 138 | DUP REM L6 (0 DUPLICATES REMOVED) |
| L8 | 33 | S L7 AND (GRAM-NEGATIVE) |

L8 ANSWER 1 OF 33 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AB Proteins in the outer membrane of **gram-negative bacteria** serve as general porins or as receptors for specific nutrient **transport systems**. Many of these proteins are also used as receptors initiating the processes of colicin or phage binding and uptake. The functional activities of several outer membrane proteins in E. coli K-12 were followed after cessation or repression of their synthesis. Cessation of receptor synthesis was accomplished with a thermolabile suppressor activity acting on amber mutations in btuB (encoding the receptor for vitamin B12, the E colicins and phage BF23) and in fepA (encoding the receptor for ferric enterochelin and colicins B and D). After cessation of receptor synthesis, cells rapidly became insensitive to the colicins using that receptor. Treatment with spectinomycin or rifampin blocked appearance of insensitive cells and even increased susceptibility to colicin E1. Insensitivity to phage BF23 appeared only after a lag of about 1 division time, and the receptors remained functional for B12 uptake throughout. Therefore, possession of receptor is insufficient for colicin sensitivity, and some interaction of receptor with subsequent uptake components is indicated. Another example of physiological alteration of colicin sensitivity is the protection against many of the tonB-dependent colicins afforded by provision of Fe-supplying siderophores. The rate of acquisition of this **nonspecific** protection was consistent with the repression of receptor synthesis, rather than through direct and immediate effects on the tonB product or other components of colicin uptake or action.
AN 1980:281305 BIOSIS
DN BA70:73801
TI OUTER MEMBRANE DEPENDENT **TRANSPORT SYSTEMS** IN ESCHERICHIA-COLI EFFECT OF REPRESSION OR CESSATION OF COLICIN RECEPTOR SYNTHESIS ON COLICIN RECEPTOR ACTIVITIES.
AU KADNER R J; MCELHANEY G
CS DEP. MICROBIOL., UNIV. VA. SCH. MED., CHARLOTTESVILLE, VA. 22908, USA.
SO J BACTERIOL, (1980) 143 (1), 135-141.
CODEN: JOBAAY. ISSN: 0021-9193.
FS BA; OLD
LA English

L8 ANSWER 2 OF 33 MEDLINE
AB Bacterial periplasmic **transport systems** are complex, multicomponent permeases, present in **Gram-negative bacteria**. Many such permeases have been analyzed to various levels of detail. A generalized picture has emerged indicating that their overall structure consists of four proteins, one of which is a soluble periplasmic protein that binds the substrate and the other three are membrane bound. The liganded periplasmic protein interacts with the membrane components, which presumably form a complex, and which by a series of conformational changes allow the formation of an entry pathway for the substrate. The two extreme alternatives for such pathway involve either the formation of a **nonspecific** hydrophilic pore or the development of a ligand-binding site(s) on the membrane-bound complex. One of the membrane-bound components from each system constitutes a family of highly homologous proteins containing sequence domains characteristic of nucleotide-binding sites. Indeed, in several cases, they have been shown to bind ATP, which is thus postulated to be involved in the energy-coupling mechanism. Interestingly, eukaryotic proteins homologous to this family of proteins have been identified (mammalian mdr genes and Drosophila white locus), thus indicating that they perform a universal function, presumably related to energy coupling in membrane-related processes. The mechanism of energy coupling in periplasmic permeases is discussed.
AN 88153630 MEDLINE
DN 88153630 PubMed ID: 3279024
TI Structure and mechanism of bacterial periplasmic **transport systems**.

AU Ames G F
CS Department of Biochemistry, University of California, Berkeley 94720.
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, (1988 Feb) 20 (1) 1-18. Ref: 86
Journal code: 7701859. ISSN: 0145-479X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 198804
ED Entered STN: 19900308
Last Updated on STN: 19900308
Entered Medline: 19880412

L8 ANSWER 3 OF 33 USPATFULL
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
AN 2003:120747 USPATFULL
TI Blood cell deficiency treatment method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)

US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428

L8 ANSWER 4 OF 33 USPATFULL
AB The invention provides isolated animal soluble adenylyl cyclase and methods of modulating its expression and activity. Also provided are methods of utilizing soluble adenylyl cyclase for diagnosing pathological conditions and monitoring blood gases.
AN 2003:95963 USPATFULL
TI Mammalian soluble adenylyl cyclase
IN Buck, Jochen, Old Greenwich, CT, United States
Levin, Lonny R., New York, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 6544768 B1 20030408
AI US 2000-568407 20000511 (9)
PRAI US 1999-133802P 19990511 (60)
US 1999-161534P 19991026 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Monshipouri, M.
LREP Darby & Darby
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 3311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 33 USPATFULL
AB The invention provides compositions comprising formula 1 steroids, e.g., 16.alpha.-bromo-3 .beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
AN 2003:86817 USPATFULL
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8

Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED

PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)

DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 33 USPATFULL

AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

AN 2003:60089 USPATFULL
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6528289 B1 20030304
AI US 2000-643990 20000823 (9)
RLI Continuation of Ser. No. US 1995-487429, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Martinell, James
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)

LN.CNT 4428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 33 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2003:13200 USPATFULL
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Science, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6506581 B1 20030114
AI US 2000-557884 20000425 (9)
RLI Continuation of Ser. No. US 1995-476102, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Brusca, John S.
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 33 USPATFULL
AB The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.
AN 2002:314381 USPATFULL
TI Card domain containing polypeptides, encoding nucleic acids, and methods of use
IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES.
Pio, Frederick F., Vancouver, CANADA
Godzik, Adam, San Diego, CA, UNITED STATES
Stehlik, Christian, San Diego, CA, UNITED STATES
Damiano, Jason S., La Jolla, CA, UNITED STATES
Lee, Sug Hyung, San Diego, CA, UNITED STATES
Oliveira, Vasco A., San Diego, CA, UNITED STATES
Hayashi, Hideki, Nagasaki City, JAPAN
Pawlowski, Krzysztof, Malmo, SWEDEN
PI US 2002176853 A1 20021128
AI US 2001-864921 A1 20010523 (9)
PRAI US 2001-275980P 20010314 (60)
US 2000-367337P 20001010 (60)
US 2000-325756P 20000524 (60)
DT Utility

FS APPLICATION
LREP CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 6136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 33 USPATFULL
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
AN 2002:295092 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002165137 A1 20021107
AI US 2001-860670 A1 20010521 (9)
RLI Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. US 2001-764859, filed on 17 Jan 2001, PENDING
PRAI US 2000-205515P 20000519 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-216880P 20000707 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-236367P 20000929 (60)
US 2000-239937P 20001013 (60)
US 2000-249210P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-231243P 20000908 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249265P 20001117 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)

US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 33 USPATFULL
AB The present invention relates to novel human secreted protein (HNFGF20). Polypeptides of the invention are duseful in dianosis and treatment of disorders affecting the immune system.
AN 2002:291062 USPATFULL
TI Secreted protein HNFGF20
IN Komatsoulis, George, Silver Spring, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Ruben, Steven M., Olney, MD, United States
Duan, Roxanne D., Bethesda, MD, United States
Moore, Paul A., Germantown, MD, United States
Shi, Yanggu, Gaithersburg, MD, United States
LaFleur, David W., Washington, DC, United States
Wei, Ying-Fei, Berkeley, CA, United States
Ni, Jian, Rockville, MD, United States
Florence, Kimberly A., Rockville, MD, United States
Young, Paul, Gaithersburg, MD, United States
Brewer, Laurie A., St. Paul, MN, United States
Soppet, Daniel R., Centreville, VA, United States
Endress, Gregory A., Potomac, MD, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Olsen, Henrik, Gaithersburg, MD, United States
Mucenski, Michael, Cincinnati, OH, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6476195 B1 20021105
AI US 2000-489847 20000124 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US17130, filed on 29 Jul 1999
PRAI US 1998-94657P 19980730 (60)
US 1998-95486P 19980805 (60)
US 1998-96319P 19980812 (60)
US 1998-95454P 19980806 (60)
US 1998-95455P 19980806 (60)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Goldberg, Jeanine
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 36
ECL Exemplary Claim: 1,7
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 20107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 33 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2002:275915 USPATFULL
TI Selected Haemophilus influenzae Rd polynucleotides and polypeptides
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6468765 B1 20021022
AI US 1995-487429 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Martinell, James
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 87
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 33 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2002:209560 USPATFULL
TI Peptidomimetic efflux pump inhibitors
IN Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
She, Miles, Oakland, CA, United States
PA Essential Therapeutics, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6436980 B1 20020820
AI US 2000-724818 20001128 (9)
RLI Division of Ser. No. US 1998-89734, filed on 3 Jun 1998, now patented, Pat. No. US 6204279
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Khare, Devesh
LREP Lyon & Lyon LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 33 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2002:129983 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Ishida, Yohei, Tokyo, JAPAN
Lee, Ving J, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Nakayama, Kiyoshi, Chiba, JAPAN
Ohta, Toshiharu, Tokyo, JAPAN
Ohtsuka, Masami, Tokyo, JAPAN
Reñau, Thomas E., Santa Clara, CA, United States
Watkins, William J., Sunnyvale, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6399629 B1 20020604
AI US 1998-108906 19980701 (9)
PRAI US 1998-87514P 19980601 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Lambkin, Deborah C.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 8273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 33 USPATFULL
AB The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.
AN 2002:105961 USPATFULL
TI Streptococcus suis vaccines and diagnostic tests
IN Smith, Hilda E., Lelystad, NETHERLANDS
PI US 2002055168 A1 20020509
AI US 2001-767041 A1 20010122 (9)
RLI Continuation of Ser. No. WO 1999-NL460, filed on 19 Jul 1999, UNKNOWN
PRAI EP 1998-202465 19980722
DT Utility
FS APPLICATION
LREP TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 59 Drawing Page(s)
LN.CNT 4678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 33 USPATFULL
AB The present invention provides an oligonucleotide (aarC) which encodes a novel bacterial polypeptide (AarC) that is essential for the viability of **bacteria**. The invention provides recombinant expression

vectors comprising the nucleotide sequence encoding AarC, as well as host cells containing these expression vectors. Further provided herein are methods for screening **bacteria** which contain aarC or variants or homologs thereof. Also provided are methods for using the aarC oligonucleotide sequence to screen antimicrobials which target AarC activity in **gram negative** and gram positive **bacteria**. Additionally, the invention provides for the use of aarC in diagnostic assays which utilize the aarC oligonucleotide to hybridize with nucleic acid sequences encoding AarC as well as with AarC mRNA. The invention further describes monoclonal and polyclonal AarC antibodies and their use in diagnostic assays for the detection of **bacteria** which express AarC.

AN 2002:102260 USPATFULL
TI Methods of screening for anti-microbial utilizing aarC and compositions thereof
IN Rather, Philip N., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6383745 B1 20020507
AI US 1998-170187 19981013 (9)
RLI Division of Ser. No. US 1997-827190, filed on 27 Mar 1997, now patented, Pat. No. US 5858367
DT Utility
FS GRANTED
EXNAM Primary Examiner: Graser, Jennifer E.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 33 USPATFULL
AB Single-molecule selection methods are provided for identifying target-binding molecules from diverse sequence and shape libraries. Complexes and imprints of selected target-binding molecules are also provided. The subject selection methods are used to identify oligonucleotide and nonnucleotide molecules with desirable properties for use in pharmaceuticals, drug discovery, drug delivery, diagnostics, medical devices, cosmetics, agriculture, environmental remediation, smart materials, packaging, microelectronics and nanofabrication. Single oligonucleotide molecules with desirable binding properties are selected from diverse sequence libraries and identified by amplification and sequencing. Alternatively, selected oligonucleotide molecules are identified by sequencing without amplification. Nonnucleotide molecules with desirable properties are identified by single-molecule selection from libraries of conjugated molecules or nucleotide-encoded nonnucleotide molecules. Alternatively, target-specific nonnucleotide molecules are prepared by imprinting selected oligonucleotide molecules into nonnucleotide molecular media. Complexes and imprints of molecules identified by single-molecule selection are shown to have broad utility as drugs, prodrugs, drug delivery systems, willfully reversible cosmetics, diagnostic reagents, sensors, transducers, actuators, adhesives, adherents and novel multimolecular devices.
AN 2002:60923 USPATFULL
TI Single-molecule selection methods and compositions therefrom
IN Cubicciotti, Roger S., Montclair, NJ, UNITED STATES
PI US 2002034757 A1 20020321
AI US 2001-907385 A1 20010717 (9)
RLI Continuation of Ser. No. US 1998-81930, filed on 20 May 1998, GRANTED, Pat. No. US 6287765
DT Utility
FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053

CLMN Number of Claims: 129
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 33 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2002:50802 USPATFULL
TI Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6355450 B1 20020312
AI US 1995-476102 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Campell, Bruce R.
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 33 USPATFULL
AB Multimolecular devices and drug delivery systems prepared from synthetic heteropolymers, heteropolymeric discrete structures, multivalent heteropolymeric hybrid structures, aptameric multimolecular devices, multivalent imprints, tethered specific recognition devices, paired specific recognition devices, nonaptameric multimolecular devices and immobilized multimolecular structures are provided, including molecular adsorbents and multimolecular adherents, adhesives, transducers, switches, sensors and delivery systems. Methods for selecting single synthetic nucleotides, shape-specific probes and specifically attractive surfaces for use in these multimolecular devices are also provided. In addition, paired nucleotide-nonnucleotide mapping libraries for transposition of selected populations of selected nonoligonucleotide molecules into selected populations of replicatable nucleotide sequences are described.
AN 2001:152673 USPATFULL
TI Methods for detecting and identifying single molecules
IN Cubicciotti, Roger S., Montclair, NJ, United States
PA Molecular Machines, Inc., Montclair, NJ, United States (U.S. corporation)
PI US 6287765 B1 20010911
AI US 1998-81930 19980520 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey

LREP Licata & Tyrrell P.C.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 33 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2001:86448 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Lee, May, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
Renau, Thomas, Santa Clara, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6245746 B1 20010612
AI US 1998-20001 19980204 (9)
RLI Continuation-in-part of Ser. No. US 1998-12363, filed on 23 Jan 1998, now patented, Pat. No. US 6114310
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 33 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2001:40493 USPATFULL
TI Peptidomimetic efflux pump inhibitors
IN Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
She, Miles, Oakland, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6204279 B1 20010320
AI US 1998-89734 19980603 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Howard C.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 33 USPATFULL
AB Methods for obtaining surface expression of a desired protein or polypeptide in Gram-positive host organisms are provided. In addition, vectors useful in such methods as well as Gram-positive host organisms transformed with such vectors are disclosed.
AN 2001:25429 USPATFULL

TI Materials and methods relating to the attachment and display of substances on cell surfaces
IN Steidler, Lothar, Ghent, Belgium
Remaut, Erik, Ghent, Belgium
Wells, Jeremy Mark, Cambridge, United Kingdom
PA Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) vzw, Zwijnaarde, Belgium (non-U.S. corporation)
PI US 6190662 B1 20010220
AI US 1998-36609 19980306 (9)
RLI Continuation of Ser. No. WO 1996-GB2195, filed on 6 Sep 1996
PRAI GB 1995-18323 19950907
DT Utility
FS Granted
EXNAM Primary Examiner: Navarro, Albert
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 33 USPATFULL
AB The present invention is directed to oligonucleotides used as amplification primers and assay probes for specific and sensitive for virulent strains of V. vulnificus. The target sequence of the probes and primers according to present invention is a capsular polysaccharide (CPS) transport gene (wza) of V. vulnificus. These probes can detect wza DNA or RNA in an unknown sample suspected to have pathogenic strains of V. vulnificus including human, animal, or environmental samples. The invention is also directed to in vitro-expressed protein from the cloned wza for production of polyclonal or monoclonal antibody that is specific for the wza gene product and will detect the V. vulnificus Wza protein in a sample comprising unknown protein.
AN 2001:18221 USPATFULL
TI Vibrio vulnificus molecular probes, antibodies, and proteins
IN Wright, Anita C., Woodstock, MD, United States
Powell, Jan L., Baltimore, MD, United States
Morris, Jr., J. Glenn, Baltimore, MD, United States
PA UMBI - University of Maryland Biotechnology Institute, Baltimore, MD, United States (U.S. corporation)
PI US 6183973 B1 20010206
AI US 1998-205283 19981204 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US1467, filed on 19 Jun 1998
PRAI US 1997-50243P 19970619 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Lu, Frank
LREP Blank Rome Comisky & McCauley LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 33 USPATFULL
AB A novel gene encoding a 37 kDa outer membrane protein from Campylobacter coli M275 has been cloned and sequenced. This protein has been named CadF and is expressed in a large number of clinical isolates of Campylobacter species. The invention also provides assays for detecting the presence of pathogenic Campylobacter species based on the antibody-based detection of CadF, or the polymerase chain reaction (PCR)-based amplification of a segment of the C. coli cadF gene.
AN 2000:164305 USPATFULL
TI Identification and molecular cloning of a gene encoding a fibronectin

binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
IN Konkel, Michael E., Pullman, WA, United States
Garvis, Steven G., Pullman, WA, United States
PA Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)
PI US 6156546 20001205
AI US 1998-80025 19980515 (9)
PRAI US 1997-46763P 19970516 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Fredman, Jeffrey; Assistant Examiner: Einsmann, Juliet C.
LREP Christensen O'Connor Johnson & Kindness PLLC
CLMN Number of Claims: 14
ECL Exemplary Claim: 14
DRWN No Drawings
LN.CNT 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 33 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2000:117691 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Lee, May, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
Renau, Thomas, Santa Clara, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6114310 20000905
AI US 1998-12363 19980123 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E
LREP Lyon & Lyon LLP
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 33 USPATFULL
AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 2000:7062 USPATFULL
TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockfeller University, New York, NY, United States (U.S. corporation)
PI US 6015560 20000118
AI US 1995-465966 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation of Ser. No. WO 1992-US3725, filed on 4 May 1992 which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Minnifield, Nita
LREP Klauber & Jackson
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 33 USPATFULL
AB Methods are provided for screening for inhibitors of microbial efflux pumps including those which export antibiotics. The screening methods are based on the increase in the intracellular concentration of a compound, such as an antibiotic, when the bacterial cells are contacted with an efflux pump inhibitor. In addition, this invention provides pharmaceutical compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions.
AN 1999:150935 USPATFULL
TI Method for screening for non-tetracycline efflux pump inhibitors
IN Trias, Joaquim, San Mateo, CA, United States
Chamberland, Suzanne, Los Gatos, CA, United States
Hecker, Scott J., Los Gatos, CA, United States
Lee, Ving J., Los Altos, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5989832 19991123
AI US 1995-427088 19950421 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Pak, Michael
LREP Lyon & Lyon LLP
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 33 USPATFULL
AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 1999:128131 USPATFULL
TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5968512 19991019
AI US 1995-465965 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation of Ser. No. WO 1992-US3725, filed on 4 May 1992 which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Minnifield, Nita
LREP Klauber & Jackson
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 33 USPATFULL

AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 1999:88796 USPATFULL
TI Peptides which inhibit adhesion between leukocytes and endothelial cells
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5932217 19990803
AI US 1994-348353 19941130 (8)
RLI Continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 140136
DT Utility
FS Granted
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark
LREP Klauber & Jackson
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 33 USPATFULL
AB The present invention provides an oligonucleotide (aarC) which encodes a novel bacterial polypeptide (AarC) that is essential for the viability of **bacteria**. The invention provides recombinant expression vectors comprising the nucleotide sequence encoding AarC, as well as host cells containing these expression vectors. Further provided herein are methods for screening **bacteria** which contain aarC or variants or homologs thereof. Also provided are methods for using the aarC oligonucleotide sequence to screen antimicrobials which target AarC activity in **gram negative** and gram positive **bacteria**. Additionally, the invention provides for the use of aarC in diagnostic assays which utilize the aarC oligonucleotide to hybridize with nucleic acid sequences encoding AarC as well as with AarC mRNA. The invention further describes monoclonal and polyclonal AarC antibodies and their use in diagnostic assays for the detection of **bacteria** which express AarC.
AN 1999:4040 USPATFULL
TI Methods for screening for antimicrobials utilizing AarC and compositions thereof
IN Rather, Philip N., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 5858367 19990112
AI US 1997-827190 19970327 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 33 USPATFULL
AB The invention features a Salmonella cell the virulence of which is attenuated by a deletion of a portion of the PhoQ gene and Salmonella cells having a deletion of the PhoQ gene and a deletion of the PhoP gene. The invention also features vaccines comprising such **bacteria**.
AN 1998:150449 USPATFULL

TI Salmonella vaccines
IN Miller, Samuel I., Seattle, WA, United States
Mekalanos, John J., Cambridge, MA, United States
PA The General Hospital Corporation, Boston, MS, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MS, United States (U.S. corporation)
PI US 5843426 19981201
AI US 1995-565861 19951201 (8)
RLI Continuation-in-part of Ser. No. US 1994-271354, filed on 6 Jul 1994, now patented, Pat. No. US 5695983 which is a continuation-in-part of Ser. No. US 1993-90526, filed on 9 Jul 1993, now patented, Pat. No. US 5599537 which is a continuation-in-part of Ser. No. US 1990-629602, filed on 18 Dec 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuvader, John L.; Assistant Examiner: Brusca, John S.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 4505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 33 USPATFULL
AB Peptides and antibodies which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents and a method of increasing the permeability of the blood-brain barrier using an antibody to the Arg-Gly-Asp (RGD) region of filamentous hemagglutinin (FHA) are described.
AN 1998:95235 USPATFULL
TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5792457 19980811
AI US 1995-465929 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Krikorian, Jacqueline G.
LREP Klauber & Jackson
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 2578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 33 USPATFULL
AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of

microorganisms, including Chromobacterium violaceum and Chlorella vuloaris.
AN 94:17767 USPATFULL
TI Processes to recover and reconcentrate gold from its ores
IN Kleid, Dennis G., Foster, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., Oakland, CA, United States
PA Geobiotics, Inc., Hayward, CA, United States (U.S. corporation)
PI US 5290526 19940301
AI US 1992-907919 19920701 (7)
DCD 20091006
RLI Continuation of Ser. No. US 1991-677592, filed on 26 Mar 1991, now patented, Pat. No. US 5152969 which is a continuation of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven
LREP Lyon & Lyon
CLMN Number of Claims: 16
ECL Exemplary Claim: 6
DRWN No Drawings
LN.CNT 1439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 33 USPATFULL
AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of microorganisms, including Chromobacterium violcaceum and Chlorella vulgaris.
AN 92:82551 USPATFULL
TI Processes to recover and reconcentrate gold from its ores with microorganisms
IN Kleid, Dennis G., Foster City, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., Palo Alto, CA, United States
PA Geobiotics, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5152969 19921006
AI US 1991-677592 19910326 (7)
RLI Continuation of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven
LREP Lyon & Lyon
CLMN Number of Claims: 11
ECL Exemplary Claim: 5
DRWN No Drawings
LN.CNT 1372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

ANSWER 1 OF 138 USPATFULL

AB A treatment method and genetic vectors are disclosed for non-invasive delivery of polypeptides through the blood brain barrier (BBB), to treat brain or spinal tissue. A genetic vector is used to transfect one or more neurons which "straddle" the BBB, such as sensory neurons, nocioceptive neurons, or lower motor neurons; this is done by administering the vector in a manner that causes it to contact neuronal projections that extend outside the BBB. Once inside a peripheral projection that belongs to a BBB-straddling neuron, the vectors (or some portion thereof) will be transported to the main cell body of the neuron, through a process called retrograde transport. Inside the main cell body, at least one gene carried by the genetic vector will be expressed, to form polypeptides. Some of these polypeptides (which can include leader sequences that will promote anterograde transport and secretion by BBB-straddling neurons) will be transported by the neurons to secretion sites inside the BBB. The polypeptides will be secreted by transfected neurons at locations inside the BBB, and will then contact and exert their effects upon secondary "target" neurons located entirely within the BBB. By using this system, polypeptides that stimulate nerve growth or activity can be used to treat neurodegenerative diseases, impaired limbs in stroke victims, etc., and polypeptides that suppress neuronal activity can be used to treat unwanted excessive neuronal activity, such as neuropathic pain. This approach also provides new methods for delivering endocrine and paracrine polypeptides into the CNS, thereby allowing improved medical and reproductive treatments in humans, and improved ability to modulate growth, maturation, reproduction, or other endocrine-related functions among livestock, endangered species, and other animals.

AN 2003:120815 USPATFULL

TI Non-invasive delivery of polypeptides through the blood-brain barrier

IN Ferguson, Ian A., Adelaide, AUSTRALIA

PI US 2003083299 A1 20030501

AI US 2002-188184 A1 20020702 (10)

RLI Continuation-in-part of Ser. No. US 2000-705428, filed on 4 Nov 2000, ABANDONED

DT Utility

FS APPLICATION

LREP Patrick D. Kelly, 11939 Manchester Rd. #403, St. Louis, MO, 63131

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 5424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 138 USPATFULL

AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

AN 2003:120747 USPATFULL

TI Blood cell deficiency treatment method

IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND

PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428

L7 ANSWER 3 OF 138 USPATFULL
AB The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.
AN 2003:120094 USPATFULL
TI In vivo incorporation of unnatural amino acids
IN Schultz, Peter, La Jolla, CA, UNITED STATES
Wang, Lei, San Diego, CA, UNITED STATES
Anderson, John Christopher, San Diego, CA, UNITED STATES
Chin, Jason William, San Diego, CA, UNITED STATES
Liu, David R., Lexington, MA, UNITED STATES
Magliery, Thomas J., North Haven, CT, UNITED STATES
Meggers, Eric L., Philadelphia, PA, UNITED STATES
Mehl, Ryan A., San Diego, CA, UNITED STATES
Pastrnak, Miro, San Diego, CA, UNITED STATES
Santoro, Stephen William, San Diego, CA, UNITED STATES
Zhang, Zhiwen, San Diego, CA, UNITED STATES
PA The Scripps Research Institute, La Jolla, CA, UNITED STATES, 92073 (U.S. corporation)
PI US 2003082575 A1 20030501
AI US 2002-126927 A1 20020419 (10)
PRAI US 2001-285030P 20010419 (60)
US 2002-355514P 20020206 (60)
DT Utility
FS APPLICATION

LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 140
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 6984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 138 USPATFULL
AB The present invention relates to newly identified human transporters. In particular, the invention relates to transporter polypeptides and polynucleotides, methods of detecting the transporter polypeptides and polynucleotides, and methods of diagnosing and treating transporter-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
AN 2003:112894 USPATFULL
TI 20685, 579, 17114, 23821, 33894 and 32613, novel human transporters
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003077626 A1 20030424
AI US 2002-199485 A1 20020718 (10)
RLI Continuation-in-part of Ser. No. US 2001-795693, filed on 28 Feb 2001, PENDING
PRAI US 2000-185906P 20000229 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 79 Drawing Page(s)
LN.CNT 8163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 138 USPATFULL
AB The present invention relates to methods for learning structural information about a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to one molecule or molecular complex and not to one or more other molecules or molecular complexes. Other methods that are provided can be used to identify a compound that binds to at least two molecules or molecular complexes.
AN 2003:99724 USPATFULL
TI Proteins and druggable regions of proteins
IN Edwards, Aled, Toronto, CANADA
Arrowsmith, Cheryl, North York, CANADA
Greenblatt, Jack, Toronto, CANADA
Mendlein, John D., Encincitas, CA, UNITED STATES
PI US 2003068831 A1 20030410
AI US 2002-97125 A1 20020312 (10)
PRAI US 2001-275216P 20010312 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 138 USPATFULL

AB The present invention relates to methods for learning structural information about a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to one molecule or molecular complex and not to one or more other molecules or molecular complexes. Other methods that are provided can be used to identify a compound that binds to at least two molecules or molecular complexes.
AN 2003:99546 USPATFULL
TI Multi-target analysis of gene families for chemistry of high affinity and selective small molecules and other therapeutics
IN Arrowsmith, Cheryl, North York, CANADA
Greenblatt, Jack, Toronto, CANADA
Edwards, Aled, Toronto, CANADA
Mendlein, John D., Encincitas, CA, UNITED STATES
PI US 2003068651 A1 20030410
AI US 2002-97194 A1 20020312 (10)
PRAI US 2001-275216P 20010312 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 138 USPATFULL
AB The present invention relates to methods for learning structural information about a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to a molecule or molecular complex. The invention also provides methods for identifying a compound that binds to one molecule or molecular complex and not to one or more other molecules or molecular complexes. Other methods that are provided can be used to identify a compound that binds to at least two molecules or molecular complexes.
AN 2003:99545 USPATFULL
TI Target analysis for chemistry of specific and broad spectrum anti-infectives and other therapeutics
IN Greenblatt, Jack, Toronto, CANADA
Edwards, Aled, Toronto, CANADA
Arrowsmith, Cheryl, North York, CANADA
Mendlein, John D., Encincitas, CA, UNITED STATES
PI US 2003068650 A1 20030410
AI US 2002-97193 A1 20020312 (10)
PRAI US 2001-275216P 20010312 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 138 USPATFULL
AB The invention provides compositions comprising formula 1 steroids, e.g., 16.alpha.-bromo-3 .beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid

compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

AN 2003:86817 USPATFULL

TI Immune modulation method using steroid compounds

IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Francke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES

PI US 2003060425 A1 20030327

AI US 2001-820483 A1 20010329 (9)

RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED

PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)

DT Utility

FS APPLICATION

LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121

CLMN Number of Claims: 54

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 14708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 138 USPATFULL

AB The present invention contemplates monitoring the amplification of nucleic acid using chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor-donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore, and methods using the photonic structures.

AN 2003:78441 USPATFULL

TI Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
IN Heller, Michael J., Encinitas, CA, UNITED STATES
PA Nanogen, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
PI US 2003054361 A1 20030320
AI US 2001-997374 A1 20011129 (9)
RLI Continuation of Ser. No. US 2000-724753, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1998-123638, filed on 28 Jul 1998, GRANTED, Pat. No. US 6162603 Continuation of Ser. No. US 1994-232233, filed on 5 May 1994, GRANTED, Pat. No. US 5565322 A 371 of International Ser. No. WO 1992-US9827, filed on 6 Nov 1992, UNKNOWN Continuation-in-part of Ser. No. US 1994-250951, filed on 27 May 1994, PATENTED Continuation of Ser. No. US 1991-790262, filed on 7 Nov 1991, ABANDONED
DT Utility
FS APPLICATION
LREP LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 138 USPATFULL
AB In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases.
AN 2003:71417 USPATFULL
TI Novel death domain proteins
IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES
Godzik, Adam, San Diego, CA, UNITED STATES
Pawlowski, Krzysztof, Malmo, SWEDEN
Fiorentino, Loredana, San Diego, CA, UNITED STATES
Lee, Sug Hyung, Seoul, KOREA, REPUBLIC OF
Roth, Wilfried, La Jolla, CA, UNITED STATES
Stenner-Liewen, Frank, Homburg/Saar, GERMANY, FEDERAL REPUBLIC OF
PI US 2003049702 A1 20030313
AI US 2001-1254 A1 20011115 (10)
PRAI US 2001-301889P 20010629 (60)
US 2000-367360P 20001117 (60)
DT Utility
FS APPLICATION
LREP CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 5011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 138 USPATFULL
AB The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The

invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

AN 2003:51117 USPATFULL

TI Novel nucleic acid sequences encoding human transporters, a human atpase molecule, a human ubiquitin hydrolase-like molecule, a human ubiquitin conjugating enzyme-like molecule, and uses therefor

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Kapeller-Libermann, Rosanna, Chestnut Hill, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003036074 A1 20030220

AI US 2002-156239 A1 20020524 (10)

RLI Continuation-in-part of Ser. No. US 2001-795693, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-809557, filed on 15 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-808568, filed on 14 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-808767, filed on 15 Mar 2001, PENDING

PRAI US 2000-185906P 20000229 (60)
US 2000-192018P 20000324 (60)
US 2000-191790P 20000324 (60)
US 2000-191781P 20000324 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 106 Drawing Page(s)

LN.CNT 19568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 138 USPATFULL

AB The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.

AN 2003:45282 USPATFULL

TI Intracellular delivery of biological effectors

IN Bonny, Christophe, Morges, SWITZERLAND

PI US 2003032594 A1 20030213

AI US 2002-165015 A1 20020607 (10)

RLI Continuation-in-part of Ser. No. US 2001-977831, filed on 15 Oct 2001, PENDING

PRAI US 2000-240315P 20001013 (60)

DT Utility

FS APPLICATION

LREP Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA, 02111

CLMN Number of Claims: 46

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1804

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 138 USPATFULL

AB The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention

further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.

AN 2003:29837 USPATFULL
TI Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IN Dan, Michael D., Scarborough, CANADA
Maiti, Pradip K., Winnipeg, CANADA
Kaplan, Howard A., Winnipeg, CANADA
PI US 2003021779 A1 20030130
AI US 2001-782397 A1 20010213 (9)
RLI Continuation of Ser. No. US 1997-862124, filed on 22 May 1997, GRANTED, Pat. No. US 6207153 Continuation-in-part of Ser. No. US 1996-657449, filed on 22 May 1996, ABANDONED
DT Utility
FS APPLICATION
LREP SUSAN K. LEHNHARDT, FROMMER LAWRENCE & HAUG LLP, 745 Fifth Avenue, New York, NY, 10151
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 3580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 138 USPATFULL
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
AN 2003:10685 USPATFULL
TI Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IN FOWLKES, DANA MERRIMAN, CHAPEL HILL, NC, UNITED STATES
BROACH, JIM, PRINCETON, NJ, UNITED STATES
MANFREDI, JOHN, NEW YORK, NY, UNITED STATES
KLEIN, CHRISTINE, NEW YORK, NY, UNITED STATES
MURPHY, ANDREW J., MONTCLAIR, NJ, UNITED STATES
PAUL, DR. JEREMY, SOUTH NYACK, NY, UNITED STATES
TRUEHEART, JOSHUA, SOUTH NYACK, NY, UNITED STATES
PI US 2003008380 A1 20030109
AI US 1999-309196 A1 19990510 (9)
RLI Continuation of Ser. No. US 1994-322137, filed on 13 Oct 1994, GRANTED, Pat. No. US 6100042 Continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, ABANDONED
DT Utility
FS APPLICATION
LREP GIULIO A. DECONTI, JR., LAHIVE & COCKFIELD, LLP, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 5791
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 138 USPATFULL
AB Disclosed is a method of preventing, inhibiting, and/or ameliorating cell death and/or tissue necrosis in live tissue containing neural thread proteins (NTP) by contacting the live tissue with at least an antibody, antibody fragment or antibody derivative that recognizes or binds to NTP, where the antibody, antibody fragment or antibody derivative is present in an amount effective to prevent, inhibit, reduce, control and/or ameliorate cell death and/or tissue necrosis. The method is capable of treating conditions requiring prevention, inhibition, reduction, control and/or amelioration of cell death and/or tissue necrosis caused by the presence of NTP.
AN 2003:3410 USPATFULL
TI Method of preventing cell death using antibodies to neural thread proteins
IN Averback, Paul A., Quebec, CANADA
PI US 2003003445 A1 20030102
AI US 2002-138516 A1 20020506 (10)
PRAI US 2001-288463P 20010504 (60)
DT Utility
FS APPLICATION
LREP HUNTON & WILLIAMS, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 138 USPATFULL
AB The present invention relates to mouse and human cDNAs for a gene family designated Nramp (natural resistance-associated macrophage protein), involved in macrophage function and responsible for the natural resistance to infection with intracellular parasites, and to the isolation of Nramp sequences from other animal sources. The nucleotide sequences of the mouse and human cDNAs are disclosed, as are the amino sequences of the encoded products. The cDNAs can be expressed in expression constructs. These expression constructs and the proteins produced therefrom can be used for a variety of purposes including diagnostic and therapeutic methods.
AN 2003:108962 USPATFULL
TI Methods of screening for compounds that regulate the level of Nramp
IN Gros, Philippe, St-Lambert, CANADA
Skamene, Emil, Montreal, CANADA
Malo, Danielle, Montreal, CANADA
Vidal, Silvia, Ottawa, CANADA
PA McGill University, Montreal, CANADA (non-U.S. corporation)
PI US 6551781 B1 20030422
AI US 2000-614957 20000712 (9)
RLI Continuation of Ser. No. US 637823, now patented, Pat. No. US 6184031 Continuation-in-part of Ser. No. US 1994-235405, filed on 28 Apr 1994, now abandoned Continuation-in-part of Ser. No. US 1993-148481, filed on 8 Nov 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.
LREP Klauber & Jackson
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 3060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 138 USPATFULL
AB The sequences of cDNAs encoding secreted proteins are disclosed. The

cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.

AN 2003:102443 USPATFULL
TI Complementary DNA's encoding proteins with signal peptides
IN Edwards, Jean-Baptiste Dumas Milne, Paris, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Jobert, Severin, Paris, FRANCE
PA Genset, S.A., FRANCE (non-U.S. corporation)
PI US 6548633 B1 20030415
AI US 2000-599360 20000621 (9)
RLI Continuation-in-part of Ser. No. US 1999-469099, filed on 21 Dec 1999, now abandoned
PRAI US 1999-141032P 19990625 (60)
US 1998-113686P 19981222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Kim, Young
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 13743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 138 USPATFULL
AB The invention provides isolated animal soluble adenylyl cyclase and methods of modulating its expression and activity. Also provided are methods of utilizing soluble adenylyl cyclase for diagnosing pathological conditions and monitoring blood gases.
AN 2003:95963 USPATFULL
TI Mammalian soluble adenylyl cyclase
IN Buck, Jochen, Old Greenwich, CT, United States
Levin, Lonny R., New York, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 6544768 B1 20030408
AI US 2000-568407 20000511 (9)
PRAI US 1999-133802P 19990511 (60)
US 1999-161534P 19991026 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Monshipouri, M.
LREP Darby & Darby
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 3311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 138 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2003:60089 USPATFULL
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments

thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6528289 B1 20030304
AI US 2000-643990 20000823 (9)
RLI Continuation of Ser. No. US 1995-487429, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Martinell, James
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 138 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2003:13200 USPATFULL
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Science, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6506581 B1 20030114
AI US 2000-557884 20000425 (9)
RLI Continuation of Ser. No. US 1995-476102, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Brusca, John S.
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 138 USPATFULL
AB This invention relates to the discovery of nucleic acids associated with

cell proliferation, cell cycle arrest, cell death and premature aging and uses therefor.
AN 2002:343876 USPATFULL
TI NUCLEIC ACID SEQUENCES AND PROTEINS ASSOCIATED WITH AGING
IN BURMER, GLENNA C., SEATTLE, WA, UNITED STATES
BROWN, JOSEPH P., SEATTLE, WA, UNITED STATES
PI US 2002197602 A1 20021226
AI US 1999-292758 A1 19990414 (9)
PRAI US 1998-81887P 19980415 (60)
DT Utility
FS APPLICATION
LREP EUGENIA GARRETT WACKOWSKI, TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 941113834
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 138 USPATFULL
AB Apparatus and methods for modulating flow rates in microfluidic devices are provided. The methods involve modulating downstream pressure in the device to change the flow rate of materials in an upstream region of the device. Such methods include electrokinetic injection or withdrawal of materials through a side channel and the use of an absorbent material to induce wicking in the channel system. The apparatus provided includes a prefabricated wick in the device to provide for flow rate control. Additional methods for determining velocity of a particle and cell incubation time are also provided.
AN 2002:319320 USPATFULL
TI Method and apparatus for continuous liquid flow in microscale channels using pressure injection, wicking, and electrokinetic injection
IN Alajoki, Marja Liisa, Palo Alto, CA, UNITED STATES
Wada, H. Garrett, Atherton, CA, UNITED STATES
Dubrow, Robert S., San Carlos, CA, UNITED STATES
PA Caliper Technologies Corp., Mountain View, CA (U.S. corporation)
PI US 2002179445 A1 20021205
AI US 2002-142263 A1 20020508 (10)
RLI Continuation of Ser. No. US 1999-245627, filed on 5 Feb 1999, GRANTED, Pat. No. US 6416642
PRAI US 1999-116602P 19990121 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 2121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 138 USPATFULL
AB The invention provides isolated nucleic acid molecules, designated HAAT nucleic acid molecules, which encode novel phospholipid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HAAT nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a HAAT gene has been introduced or disrupted. The invention still further provides isolated HAAT proteins, fusion proteins, antigenic peptides and anti-HAAT antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
AN 2002:314671 USPATFULL
TI FBH58295FL, a novel human amino acid transporter and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2002177148 A1 20021128
AI US 2002-55025 A1 20020122 (10)
PRAI US 2001-263169P 20010122 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 138 USPATFULL
AB This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.
AN 2002:314670 USPATFULL
TI Mdr1 variants and methods for their use
IN Mealey, Katrina L., Pullman, WA, UNITED STATES
Bentjen, Steven A., Troy, ID, UNITED STATES
PA Washington State University Research Foundation (U.S. corporation)
PI US 2002177147 A1 20021128
AI US 2002-44671 A1 20020110 (10)
PRAI US 2001-261578P 20010112 (60)
US 2001-314829P 20010824 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 SW SALMON STREET, SUITE 1600, PORTLAND, OR, 97204
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 138 USPATFULL
AB The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.
AN 2002:314381 USPATFULL
TI Card domain containing polypeptides, encoding nucleic acids, and methods of use
IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES
Pio, Frederick F., Vancouver, CANADA
Godzik, Adam, San Diego, CA, UNITED STATES
Stehlik, Christian, San Diego, CA, UNITED STATES
Damiano, Jason S., La Jolla, CA, UNITED STATES
Lee, Sug Hyung, San Diego, CA, UNITED STATES
Oliveira, Vasco A., San Diego, CA, UNITED STATES
Hayashi, Hideki, Nagasaki City, JAPAN
Pawlowski, Krzysztof, Malmo, SWEDEN
PI US 2002176853 A1 20021128
AI US 2001-864921 A1 20010523 (9)
PRAI US 2001-275980P 20010314 (60)
US 2000-367337P 20001010 (60)
US 2000-325756P 20000524 (60)
DT Utility

FS APPLICATION
LREP CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 6136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 138 USPATFULL
AB Disclosed are a variety of methods and computer systems for use in the analysis of gene and protein expression data. Also disclosed are methods for the definition of the cellular state of cells and tissues from multidimensional physiological data such as those obtained from gene expression measurements with DNA microarrays. A variety of classification methods can be applied to expression data to achieve this goal. Demonstrated is the application of several statistical tools including Wilks' lambda ratio of within-group to total variance, Fisher Discriminant Analysis, and the misclassification error rate to the identification of discriminating genes and the overall classification of expression data. Examples from several different cases demonstrate the ability of the method to produce well-separated groups in the projection space representing distinct physiological states. The method can be augmented and is useful in disease diagnosis, drug screening and bioprocessing applications.
AN 2002:302009 USPATFULL
TI Defining biological states and related genes, proteins and patterns
IN Stephanopoulos, Gregory, Chester, MA, UNITED STATES
Misra, Jatin, Cambridge, MA, UNITED STATES
Hwang, Daehee, Cambridge, MA, UNITED STATES
Schmitt, William A., JR., Boston, MA, UNITED STATES
Alevizos, Ilias, Watertown, MA, UNITED STATES
Silva, Saliya Sudharshana, Kandy, SRI LANKA
Gill, Ryan T., Boulde, CO, UNITED STATES
PI US 2002169562 A1 20021114
AI US 2002-60048 A1 20020129 (10)
PRAI US 2001-285186P 20010420 (60)
US 2001-264779P 20010129 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG LLP, PATENT GROUP, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 4754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 138 USPATFULL
AB A system and method for processing a lipid membrane bound structure. the method comprising the steps of providing the structure to be processed in a liquid medium; and heating the liquid medium containing the structure at a rate and through a range sufficient to cause a discrete phase transition in at least one of the membranes, such that the membranes fuse. The method may be used to fuse the structure with another structure, or to reduce the integrity of the structure. The apparatus atomizes a medium containing the structure into small droplets and subjects them to an environment containing steam vapor while moving at high velocity, to rapidly increase the droplet temperature to the steam temperature by release of the latent heat of vaporization.
AN 2002:301190 USPATFULL
TI Rapid thermal cycle processing methods and apparatus
IN Grae, Joel B., Peekskill, NY, UNITED STATES
PI US 2002168734 A1 20021114
AI US 2001-931827 A1 20010817 (9)

RLI Continuation of Ser. No. US 2000-508889, filed on 17 Mar 2000, GRANTED, Pat. No. US 6277610 A 371 of International Ser. No. WO 1998-US19815, filed on 23 Sep 1998, UNKNOWN
PRAI US 1997-60690P 19970923 (60)
DT Utility
FS APPLICATION
LREP Karl F. Milde, Jr., Esq., MILDE, HOFFBERG & MACKLIN, LLP, Suite 460, 10 Bank Street, White Plains, NY, 10606
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 138 USPATFULL
AB Genes regulated by protein kinase A comprising the catalytic subunits encoded by Tpk1, Tpk2 or Tpk3 are described. Methods for altering iron uptake, trehalose breakdown, water homeostasis and respiratory growth as well as methods for altering branched chain amino acid synthesis are described. Further, methods for inhibiting virulence in an organism are described.
AN 2002:301158 USPATFULL
TI Iron uptake and respiratory function are differentially regulated by yeast a kinases
IN Robertson, Laura S., Sheperdstown, WV, UNITED STATES
Causton, Helen Claire, London, UNITED KINGDOM
Fink, Gerald R., Chestnut Hill, MA, UNITED STATES
PI US 2002168701 A1 20021114
AI US 2000-729915 A1 20001204 (9)
PRAI US 1999-168563P 19991202 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 138 USPATFULL
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
AN 2002:295092 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002165137 A1 20021107
AI US 2001-860670 A1 20010521 (9)

RLI Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. US 2001-764859, filed on 17 Jan 2001, PENDING

PRAI US 2000-205515P 20000519 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-216880P 20000707 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-236367P 20000929 (60)
US 2000-239937P 20001013 (60)
US 2000-249210P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-231243P 20000908 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249265P 20001117 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)

DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 138 USPATFULL

AB The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for

increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.

AN 2002:260714 USPATFULL
TI Animals expressing exogenous IGF-I in their milk
IN Wheeler, Matthew B., Tolono, IL, UNITED STATES
Donovan, Sharon M., Champaign, IL, UNITED STATES
Bleck, Gregory T., Baraboo, WI, UNITED STATES
Monaco-Seigel, Marcia, Sidney, IL, UNITED STATES
PI US 2002144296 A1 20021003
AI US 2001-930377 A1 20010815 (9)
PRAI US 2000-225474P 20000815 (60)
DT Utility
FS APPLICATION
LREP GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN CIRCLE, SUITE 201, BOULDER, CO, 80303
CLMN Number of Claims: 76
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2159

L7 ANSWER 31 OF 138 USPATFULL
AB Stress and/or shear resistant retrovirus envelope protein polypeptides and nucleic acids encoding such polypeptides, as well as fragments of such nucleic acids and polypeptides and compositions thereof, are provided. Retroviruses incorporating such polypeptides and methods of using stress resistant retrovirus envelope protein polypeptides and corresponding nucleic acids are also described.

AN 2002:251931 USPATFULL
TI Stress resistant retroviruses
IN Soong, Nay Wei, San Jose, CA, UNITED STATES
Stemmer, Willem P.C., Los Gatos, CA, UNITED STATES
Powell, Sharon K., Alameda, CA, UNITED STATES
Otto, Edward, Falls Church, VA, UNITED STATES
PI US 2002137889 A1 20020926
AI US 2001-954983 A1 20010917 (9)
PRAI US 2000-233398P 20000918 (60)
DT Utility
FS APPLICATION
LREP LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 4898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 32 OF 138 USPATFULL
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

AN 2002:250825 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, UNITED STATES
Seligman, Myron L., Pleasantville, NY, UNITED STATES
PI US 2002136763 A1 20020926
AI US 2002-83327 A1 20020225 (10)
RLI A 371 of International Ser. No. WO 1997-US23879, filed on 31 Dec 1997, UNKNOWN Continuation-in-part of Ser. No. US 1999-331947, filed on 28 Jun 1999, GRANTED, Pat. No. US 6350467
PRAI US 1996-34101P 19961231 (60)
DT Utility

FS APPLICATION
LREP Steven M. Hoffberg, MILDE & HOFFBERG, LLP, SUITE 460, 10 BANK STREET, WHITE PLAINS, NY, 10606
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 138 USPATFULL
AB Nucleic acid sequences encoding peptide transporters, peptide transporters and methods of use thereof are disclosed.
AN 2002:235480 USPATFULL
TI Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
IN Knipp, Gregory T., Berkeley Heights, NJ, UNITED STATES
Herrera-Ruiz, Dea, Piscataway, NJ, UNITED STATES
PI US 2002127669 A1 20020912
AI US 2001-870956 A1 20010531 (9)
PRAI US 2000-208061P 20000531 (60)
DT Utility
FS APPLICATION
LREP DANN DORFMAN HERRELL & SKILLMAN, SUITE 720, 1601 MARKET STREET, PHILADELPHIA, PA, 19103-2307
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 138 USPATFULL
AB The invention involves a polymeric, microporous membrane material characterized by a continuous-triply-periodic, highly branched and interconnected pore space morphology having a globally uniform, pre-selected pore size, characterized by high porosity. And further involves several related methods for forming mircorporous membrane materials; including polymerization of the hydrophobic component in a ternary surfactant/water/hydrophobe cubic phase, and other thermodynamically stable or metastable phases of phase-segregated systems, especially systems which are substantially ternary or binary, and particualarly directed to applications of the novel material in: immobilization, encapsulation, and/or controlled release of biologically active agents, and other applications where a controlled pore size is necessary or advantageous.
AN 2002:191609 USPATFULL
TI STABILIZED MICROPOROUS MATERIALS
IN ANDERSON, DAVID M, AMHERST, NY, UNITED STATES
PI US 2002102674 A1 20020801
AI US 1994-272334 A1 19940707 (8)
RLI Continuation-in-part of Ser. No. US 1993-156386, filed on 22 Nov 1993, ABANDONED Continuation of Ser. No. US 1993-58045, filed on 4 May 1993, ABANDONED Continuation of Ser. No. US 1991-809231, filed on 17 Dec 1991, ABANDONED Continuation of Ser. No. US 1990-564695, filed on 7 Aug 1990, ABANDONED Continuation of Ser. No. US 1988-292615, filed on 30 Dec 1988, ABANDONED Continuation-in-part of Ser. No. US 1987-52713, filed on 20 May 1987, ABANDONED
DT Utility
FS APPLICATION
LREP David M. McConoughey, Stoll, Miskin, Hoffman and Badie, 350 Fifth Avenue, Suite 6110, New York, NY, 10118
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5912

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 138 USPATFULL
AB This invention pertains to the identification of a novel class of glutamate transporters. In particular, this invention pertains to the discovery that proteins originally considered to perform an entirely different function (BNPI, DNPI, etc.), in fact, transport glutamate into synaptic vesicles. Designated VGLUT glutamate transporters, the transporters provide good targets with which to screen for modulators of glutamate uptake into synaptic vesicles.
AN 2002:185561 USPATFULL
TI Novel glutamate transporters
IN Edwards, Robert H., San Francisco, CA, UNITED STATES
Bellocchio, Elizabeth E., Walnut Creek, CA, UNITED STATES
Fremeau, Robert T., JR., San Francisco, CA, UNITED STATES
Reimer, Richard J., San Francisco, CA, UNITED STATES
PI US 2002098473 A1 20020725
AI US 2001-915181 A1 20010724 (9)
PRAI US 2000-220556P 20000725 (60)
DT Utility
FS APPLICATION
LREP LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 3900
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, an isolated protein which is a mammalian 5-HT.sub.4 receptor, an isolated protein which is a human 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor, vectors comprising and isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4 receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4 receptor, pharmaceutical compounds related to the human 5-HT.sub.4 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT.sub.4 receptor.
AN 2002:157062 USPATFULL
TI DNA encoding 5-HT4 serotonin receptors and uses thereof
IN Gerald, Christophe P.G, Ridgewood, NJ, UNITED STATES
Hartig, Paul R., Pennington, NJ, UNITED STATES
Branchek, Theresa A., Teaneck, NJ, UNITED STATES
Weinshank, Richard L., Teaneck, NJ, UNITED STATES
PA Synaptic Pharmaceutical Corporation (U.S. corporation)
PI US 2002081661 A1 20020627
AI US 2001-989861 A1 20011119 (9)
RLI Continuation of Ser. No. US 1998-328314, filed on 3 Apr 1998, PATENTED Division of Ser. No. US 1995-446822, filed on 31 Jul 1995, PATENTED A 371 of International Ser. No. WO 1993-US12586, filed on 22 Dec 1993, UNKNOWN A 371 of International Ser. No. US 1992-996772, filed on 24 Dec 1992, PATENTED
DT Utility
FS APPLICATION
LREP John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New

York, NY, 10036
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 3177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 138 USPATFULL
AB The present invention relates to newly identified human transporters. In particular, the invention relates to transporter polypeptides and polynucleotides, methods of detecting the transporter polypeptides and polynucleotides, and methods of diagnosing and treating transporter-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
AN 2002:133852 USPATFULL
TI 20685, 579, 17114, 23821, 33894 and 32613, novel human transporters
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002068710 A1 20020606
AI US 2001-795693 A1 20010228 (9)
PRAI US 2000-185906P 20000229 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 8073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 138 USPATFULL
AB The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.
AN 2002:105961 USPATFULL
TI Streptococcus suis vaccines and diagnostic tests
IN Smith, Hilda E., Lelystad, NETHERLANDS
PI US 2002055168 A1 20020509
AI US 2001-767041 A1 20010122 (9)
RLI Continuation of Ser. No. WO 1999-NL460, filed on 19 Jul 1999, UNKNOWN
PRAI EP 1998-202465 19980722
DT Utility
FS APPLICATION
LREP TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 59 Drawing Page(s)
LN.CNT 4678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 138 USPATFULL
AB Method for eliciting an immune response in a vertebrate subject are provided involving administration of a peptide antigen to the subject in a coordinated vaccination procedure that also involves administration of a non-viral vector that encodes a T cell co-stimulatory molecule. The peptide antigen contains at least one T cell epitope and may include an epitope of a tumor antigen or an antigen of a viral or non-viral pathogen. Epitopes from tumor antigens may represent fragments or

partial amino acid sequences of p53, ras, rb, mcc, apc, dcc; nfl; VHL; MEN1, MEN2, MLM, Her-2neu, CEA, PSA; Muc1, Gp100, tyrosinase, or MART1 proteins, and often span a mutation identified in the tumor antigen. Various viral antigens may be selected, for example antigens identified in a human immunodeficiency virus (HIV), hepatitis B virus (HBV), herpes simplex virus (HSV) or human papilloma virus (HPV), for production of peptide antigens corresponding to immunogenic epitopes of the viral antigen. The peptide antigen is administered simultaneously or sequentially with administration of the vector encoding the co-stimulatory molecules. Co-stimulatory molecules useful for coordinate administration with peptide antigens to elicit an enhanced T cell-mediated immune response may be selected from B7-1, B7-2, B7-3, ICAM1, ICAM2, LFA1 or LFA2. The peptide antigen and non-viral vector encoding the T cell co-stimulatory molecule are administered to proximal target sites selected from the same, or closely-adjacent, intradermal, subcutaneous, mucosal or intratumoral sites.

AN 2002:84909 USPATFULL
TI Methods and compositions for co-stimulation of immunological responses to peptide antigens
IN Khleif, Samir, Silverspring, MD, UNITED STATES
Berzofsky, Jay, Bethesda, MD, UNITED STATES
PI US 2002044948 A1 20020418
AI US 2001-810310 A1 20010314 (9)
PRAI US 2000-189396P 20000315 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 40 OF 138 USPATFULL
AB Single-molecule selection methods are provided for identifying target-binding molecules from diverse sequence and shape libraries. Complexes and imprints of selected target-binding molecules are also provided. The subject selection methods are used to identify oligonucleotide and nonnucleotide molecules with desirable properties for use in pharmaceuticals, drug discovery, drug delivery, diagnostics, medical devices, cosmetics, agriculture, environmental remediation, smart materials, packaging, microelectronics and nanofabrication. Single oligonucleotide molecules with desirable binding properties are selected from diverse sequence libraries and identified by amplification and sequencing. Alternatively, selected oligonucleotide molecules are identified by sequencing without amplification. Nonnucleotide molecules with desirable properties are identified by single-molecule selection from libraries of conjugated molecules or nucleotide-encoded nonnucleotide molecules. Alternatively, target-specific nonnucleotide molecules are prepared by imprinting selected oligonucleotide molecules into nonnucleotide molecular media. Complexes and imprints of molecules identified by single-molecule selection are shown to have broad utility as drugs, prodrugs, drug delivery systems, willfully reversible cosmetics, diagnostic reagents, sensors, transducers, actuators, adhesives, adherents and novel multimolecular devices.

AN 2002:60923 USPATFULL
TI Single-molecule selection methods and compositions therefrom
IN Cubicciotti, Roger S., Montclair, NJ, UNITED STATES
PI US 2002034757 A1 20020321
AI US 2001-907385 A1 20010717 (9)
RLI Continuation of Ser. No. US 1998-81930, filed on 20 May 1998, GRANTED, Pat. No. US 6287765
DT Utility

FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
CLMN Number of Claims: 129
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 41 OF 138 USPATFULL
AB A method for intracellular electro-manipulation is provided. The method includes applying one or more ultrashort electric field pulse to target cells in a tissue. The ultrashort electric field pulses have sufficient amplitude and duration to modify subcellular structures in the target cells and do not exceed the breakdown field of the medium containing the target cells. The ultrashort electric field pulses can be used to treat a neoplastic condition in a patient by applying one or more ultrashort electric field pulses to at least a portion of a neoplasm in vivo. Such treatments typically involve the application of electric field pulses which have a pulse duration of no more than 1 microsecond and an amplitude of at least 10 kV/cm. An apparatus for destroying target cells in vivo is also provided. The apparatus includes a pulse generator capable of producing one or more ultrashort electric pulse outputs and a delivery system capable of directing the electric pulse output to target cells in vivo.
AN 2002:17608 USPATFULL
TI Method and apparatus for intracellular electro-manipulation
IN Schoenbach, Karl H., Norfolk, VA, UNITED STATES
Beebe, Stephen J., Norfolk, VA, UNITED STATES
Buescher, E. Stephen, Virginia Beach, VA, UNITED STATES
PI US 2002010491 A1 20020124
AI US 2001-778448 A1 20010207 (9)
PRAI US 1999-147099P 19990804 (60)
DT Utility
FS APPLICATION
LREP Charles G. Carter, FOLEY & LARDNER, Firstar Center, 777 East Wisconsin Avenue, Milwaukee, WI, 53202-5367
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 1655

L7 ANSWER 42 OF 138 USPATFULL
AB A method is described for detecting, selecting, and cloning agents that degrade DNA or promote DNA degradation. The method utilizes extra-chromosomal replicons whose replication is dependent on degradation of a host cell's DNA to screen for agents leading to degradation of cellular DNA. An agent which promotes degradation of a host cell's DNA enables the replicons to replicate, which signals the presence of agents that promote the cellular DNA degradation and allows for the isolation and amplification of such agents.
AN 2002:16837 USPATFULL
TI Methods for detecting, selecting and cloning agents that degrade or promote degradation of DNA
IN Mattson, Thomas L., Germantown, MD, UNITED STATES
PI US 2002009717 A1 20020124
US 6455259 B2 20020924
AI US 2001-903986 A1 20010713 (9)
RLI Division of Ser. No. US 1999-261764, filed on 3 Mar 1999, GRANTED, Pat. No. US 6268139
PRAI US 1998-76657P 19980303 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B MAEBIUS, FOLEY AND LARDNER, 3000 K STREET N W SUITE 500, WASHINGTON, DC, 20007-5109

CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1288
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 43 OF 138 USPATFULL
AB The present invention relates to novel human polypeptides, designated PROST 03, which exhibit an expression pattern showing a high specificity toward prostate tissues, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
AN 2002:16579 USPATFULL
TI DNA encoding a novel PROST 03 polypeptide
IN Lau, Ted, Alameda, CA, UNITED STATES
Lin, Richard J., Danville, CA, UNITED STATES
Parkes, Deborah, Hayward, CA, UNITED STATES
Parry, Gordon, Walnut Creek, CA, UNITED STATES
Schneider, Douglas W., Lafayette, CA, UNITED STATES
Steinbrecher, Renate, Walnut Creek, CA, UNITED STATES
Heuit, Pamela Toy Van, Moraga, CA, UNITED STATES
Wu, John, Carlisle, MA, UNITED STATES
PI US 2002009455 A1 20020124
AI US 2001-838785 A1 20010420 (9)
PRAI US 2000-200065P 20000427 (60)
DT Utility
FS APPLICATION
LREP Berlex Biosciences, Legal Department, 15049 San Pablo Avenue, P.O. Box 4099, Richmond, CA, 94804-0099
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 44 OF 138 USPATFULL
AB Compounds, compositions and therapeutic methods are disclosed for the treatment of the central nervous system. The compounds are derived from the disclosed assay system which tests compounds for their ability to effect neuronal remodeling and neurite outgrowth. The assay uses cell cultures which have been genetically engineered to effect the expression of apoE3 and/or apoE4. A test compound is brought into contact with engineered neuronal cells in the presence of a lipid such as .beta.-VLDL to determine the affects of the compound, if any, on the neuronal remodeling and neurite outgrowth. Compounds found to promote neurite outgrowth are used therapeutically in the treatment of diseases and/or damage to the central nervous system.
AN 2002:16563 USPATFULL
TI Compounds effecting neuron remodeling and assays for same
IN Mahley, Robert W., San Francisco, CA, UNITED STATES
Weisgraber, Karl H., Walnut Creek, CA, UNITED STATES
Pitas, Robert E., Albany, CA, UNITED STATES
PI US 2002009439 A1 20020124
AI US 2001-782757 A1 20010212 (9)
RLI Continuation-in-part of Ser. No. US 1998-70675, filed on 30 Apr 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-659785, filed on 19 Jan 1996, ABANDONED
PRAI US 1995-5550P 19951017 (60)
DT Utility
FS APPLICATION
LREP Paula A. Borden, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road,

Suite 200, Menlo Park, CA, 94025
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 45 OF 138 USPATFULL
AB This invention relates to the discovery of the association of certain nucleic acid sequences and proteins with breast cancer, the use of such sequences as a diagnostic indicator and treatments based on the association.
AN 2002:303853 USPATFULL
TI Breast cancer associated nucleic acid sequences and their associated proteins
IN Burmer, Glenna C., Seattle, WA, United States
Brown, Joseph P., Seattle, WA, United States
Ford, Amanda A., Carnation, WA, United States
PA LifeSpan BioSciences, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6482600 B1 20021119
AI US 1999-306564 19990506 (9)
PRAI US 1998-84599P 19980507 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ungar, Susan; Assistant Examiner: Davis, Minh Tam
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2376

L7 ANSWER 46 OF 138 USPATFULL
AB The present invention relates to novel human secreted protein (HNFGF20). Polypeptides of the invention are duseful in dianosis and treatment of disorders affecting the immune system.
AN 2002:291062 USPATFULL
TI Secreted protein HNFGF20
IN Komatsoulis, George, Silver Spring, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Ruben, Steven M., Olney, MD, United States
Duan, Roxanne D., Bethesda, MD, United States
Moore, Paul A., Germantown, MD, United States
Shi, Yanggu, Gaithersburg, MD, United States
LaFleur, David W., Washington, DC, United States
Wei, Ying-Fei, Berkeley, CA, United States
Ni, Jian, Rockville, MD, United States
Florence, Kimberly A., Rockville, MD, United States
Young, Paul, Gaithersburg, MD, United States
Brewer, Laurie A., St. Paul, MN, United States
Soppet, Daniel R., Centreville, VA, United States
Endress, Gregory A., Potomac, MD, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Olsen, Henrik, Gaithersburg, MD, United States
Mucenski, Michael, Cincinnati, OH, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6476195 B1 20021105
AI US 2000-489847 20000124 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US17130, filed on 29 Jul 1999
PRAI US 1998-94657P 19980730 (60)
US 1998-95486P 19980805 (60)
US 1998-96319P 19980812 (60)
US 1998-95454P 19980806 (60)

US 1998-95455P 19980806 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Goldberg, Jeanine
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 36
ECL Exemplary Claim: 1,7
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 20107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 47 OF 138 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2002:275915 USPATFULL
TI Selected Haemophilus influenzae Rd polynucleotides and polypeptides
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6468765 B1 20021022
AI US 1995-487429 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Martinell, James
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 87
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 48 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
AN 2002:230792 USPATFULL
TI DNA encoding human alpha 1 adrenergic receptors and uses thereof
IN Bard, Jonathan A., Doylestown, PA, United States
Weinshank, Richard L., Teaneck, NJ, United States
Forray, Carlos C., Paramus, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S.

corporation)
PI US 6448011 B1 20020910
AI US 2000-688415 20001016 (9)
RLI Continuation of Ser. No. US 1999-474551, filed on 29 Dec 1999, now patented, Pat. No. US 6156518 Continuation of Ser. No. US 1998-206899, filed on 7 Dec 1998, now patented, Pat. No. US 6083705 Division of Ser. No. US 406855, now patented, Pat. No. US 5861309 Continuation-in-part of Ser. No. US 1992-952798, filed on 25 Sep 1992, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wang, Andrew
LREP Dunham, Christopher C., Cooper & Dunham LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 3607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 49 OF 138 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2002:209560 USPATFULL
TI Peptidomimetic efflux pump inhibitors
IN Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
She, Miles, Oakland, CA, United States
PA Essential Therapeutics, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6436980 B1 20020820
AI US 2000-724818 20001128 (9)
RLI Division of Ser. No. US 1998-89734, filed on 3 Jun 1998, now patented, Pat. No. US 6204279
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Khare, Devesh
LREP Lyon & Lyon LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 50 OF 138 USPATFULL
AB Recombinant organisms are provided comprising genes encoding genes encoding glycerol dehydratase, 1,3-propanediol oxidoreductase, a gene encoding vitamin B.sub.12 receptor precursor(BtuB), a gene encoding vitamin B.sub.12 transport system permease protein(BtuC) and a gene encoding vitamin B.sub.12 transport ATP-binding protein (BtuD). The recombinant microorganism is contacted with a carbon substrate and 1,3-propanediol is isolated from the growth media.
AN 2002:201883 USPATFULL
TI Method for the production of 1,3-propanediol by recombinant organisms comprising genes for vitamin B12 transport
IN Bulthuis, Ben A., Hoofddorp, NETHERLANDS
Whited, Gregory M., Belmont, CA, United States
Trimbur, Donald E., Redwood City, CA, United States
Gatenby, Anthony A., Wilmington, DE, United States
PA E. I. du Pont de Nemours and Company, Wilmington, DE, United States (U.S. corporation)
Genencor International, Palo Alto, CA, United States (U.S. corporation)
PI US 6432686 B1 20020813
AI US 1999-307973 19990510 (9)
PRAI US 1998-85190P 19980512 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Monshipouri, Maryam
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 51 OF 138 USPATFULL
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.
AN 2002:181670 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopolos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6423687 B1 20020723
AI US 2001-813247 20010319 (9)
RLI Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US 6204248 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Milde & Hoffberg, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 52 OF 138 USPATFULL
AB This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.
AN 2002:175284 USPATFULL
TI Method of obtaining compositions comprising Y2 specific compounds
IN Gerald, Christophe, Ridgewood, NJ, United States
Walker, Mary W., Elmwood Park, NJ, United States
Branchek, Theresa, Teaneck, NJ, United States
Weinshank, Richard L., Teaneck, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 6420532 B1 20020716
AI US 1999-407367 19990929 (9)
RLI Continuation of Ser. No. US 1996-687355, filed on 26 Nov 1996, now patented, Pat. No. US 5989834 Continuation-in-part of Ser. No. US 1994-192288, filed on 3 Feb 1994, now patented, Pat. No. US 5545549,

issued on 13 Aug 1996
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Gucker, Stephen
LREP White, John P., Cooper & Dunham LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 3654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 53 OF 138 USPATFULL
AB The present invention contemplates chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor-donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore, and methods using the photonic structures.
AN 2002:168047 USPATFULL
TI Hybridization of polynucleotides conjugated with chromo-phores and fluorophores to generate donor-to-donor energy transfer system
IN Heller, Michael J., Encinitas, CA, United States
PA Nanogen, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6416953 B1 20020709
AI US 2000-724753 20001128 (9)
RLI Continuation of Ser. No. US 1998-123638, filed on 28 Jul 1998, now patented, Pat. No. US 6162603 Continuation of Ser. No. US 232233, now patented, Pat. No. US 5565322 Continuation-in-part of Ser. No. US 1994-250951, filed on 27 May 1994, now patented, Pat. No. US 5532129 Continuation of Ser. No. US 1991-790262, filed on 7 Nov 1991, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Lyon & Lyon LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 54 OF 138 USPATFULL
AB Apparatus and methods for modulating flow rates in microfluidic devices are provided. The methods involve modulating downstream pressure in the device to change the flow rate of materials in an upstream region of the device. Such methods include electrokinetic injection or withdrawal of materials through a side channel and the use of an absorbent material to induce wicking in the channel system. The apparatus provided includes a prefabricated wick in the device to provide for flow rate control. Additional methods for determining velocity of a particle and cell incubation time are also provided.
AN 2002:167776 USPATFULL
TI Method and apparatus for continuous liquid flow in microscale channels using pressure injection, wicking, and electrokinetic injection
IN Alajoki, Marja Liisa, Palo Alto, CA, United States
Wada, H. Garrett, Atherton, CA, United States
Dubrow, Robert S., San Carlos, CA, United States
PA Caliper Technologies Corp., Mountain View, CA, United States (U.S. corporation)

PI US 6416642 B1 20020709
AI US 1999-245627 19990205 (9)
PRAI US 1999-116602P 19990121 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Noguerola, Alex
LREP Shaver, Gulshan, Landry, Stacy, Qunie Intellectual Property Law Group, P.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1948
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 55 OF 138 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2002:129983 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Ishida, Yohei, Tokyo, JAPAN
Lee, Ving J, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Nakayama, Kiyoshi, Chiba, JAPAN
Ohta, Toshiharu, Tokyo, JAPAN
Ohtsuka, Masami, Tokyo, JAPAN
Renau, Thomas E., Santa Clara, CA, United States
Watkins, William J., Sunnyvale, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6399629 B1 20020604
AI US 1998-108906 19980701 (9)
PRAI US 1998-87514P 19980601 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Lambkin, Deborah C.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 8273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 56 OF 138 USPATFULL
AB The present invention provides an oligonucleotide (aarC) which encodes a novel bacterial polypeptide (AarC) that is essential for the viability of **bacteria**. The invention provides recombinant expression vectors comprising the nucleotide sequence encoding AarC, as well as host cells containing these expression vectors. Further provided herein are methods for screening **bacteria** which contain aarC or variants or homologs thereof. Also provided are methods for using the aarC oligonucleotide sequence to screen antimicrobials which target AarC activity in gram negative and gram positive **bacteria**. Additionally, the invention provides for the use of aarC in diagnostic assays which utilize the aarC oligonucleotide to hybridize with nucleic acid sequences encoding AarC as well as with AarC mRNA. The invention further describes monoclonal and polyclonal AarC antibodies and their use in diagnostic assays for the detection of **bacteria** which express AarC.
AN 2002:102260 USPATFULL
TI Methods of screening for anti-microbial utilizing aarC and compositions thereof

IN Rather, Philip N., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6383745 B1 20020507
AI US 1998-170187 19981013 (9)
RLI Division of Ser. No. US 1997-827190, filed on 27 Mar 1997, now patented, Pat. No. US 5858367
DT Utility
FS GRANTED
EXNAM Primary Examiner: Graser, Jennifer E.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 57 OF 138 USPATFULL
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
AN 2002:50802 USPATFULL
TI Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
IN Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6355450 B1 20020312
AI US 1995-476102 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Campell, Bruce R.
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 58 OF 138 USPATFULL
AB A method for determining the ion channel activity of a substance comprises the steps of (i) expressing the substance as a heterologous protein in a host cell, and (ii) determining changes in permeability of the plasma membrane of the host cell induced by expression of the heterologous protein. A screening method for determining ion channel modulating activity of a test substance is also disclosed.
AN 2002:50768 USPATFULL
TI Method for determining ion channel activity of a substance
IN Gage, Peter William, via Queanbeyan, AUSTRALIA
Cox, Graeme Barry, Swinger Hill, AUSTRALIA
Ewart, Gary Dinneen, Hackett, AUSTRALIA
PA Australian National University, Acton, AUSTRALIA (non-U.S. corporation)
PI US 6355413 B1 20020312

WO 9813514 19980402
AI US 1999-269278 19990630 (9)
WO 1997-NO638 19970926
19990630 PCT 371 date
PRAI AU 1996-2581 19960927
DT Utility
FS GRANTED
EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Foley, Shanon A.
LREP Burns, Doane, Swecker, & Mathis, LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 805
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 59 OF 138 USPATFULL
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.
AN 2002:39674 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6350467 B1 20020226
WO 9829101 19980709
AI US 1999-331947 19990628 (9)
WO 1997-US23879 19971231
19990628 PCT 371 date
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 60 OF 138 MEDLINE
AB At several E. coli promoters, initiation of transcription is repressed by a tight nucleoprotein complex formed by the assembly of the H-NS protein. In order to characterize the relationship between the structure of H-NS oligomers in solution and on relevant DNA fragments, we have compared wild-type H-NS and several transdominant H-NS mutants using gel shift assays, DNase I footprinting, analytical ultracentrifugation, and reactivity toward a cross-linking reagent. In solution, oligomerization occurs through two protein interfaces, one necessary to construct a dimeric core (and involving residues 1-64) and the other required for subsequent assembly of these dimers. We show that, as well as region 64-95, residues present in the NH(2)-terminal coiled coil domain also participate in this second interface. Our results support the view that the same interacting interfaces are also involved on the DNA. We propose that the dimeric core recognizes specific motifs, with the second interface being critical for their correct head to tail assembly. The COOH-terminal domain of the protein contains the DNA binding motif essential for the discrimination of this specific functional assembly over competitive **nonspecific** H-NS polymers.
AN 2002660532 MEDLINE

DN 22289374 PubMed ID: 12200432
TI The degree of oligomerization of the H-NS nucleoid structuring protein is related to specific binding to DNA.
AU Badaut Cyril; Williams Roy; Arluison Veronique; Bouffartigues Emeline; Robert Bruno; Buc Henri; Rimsky Sylvie
CS URA 1773 du CNRS, Institut Pasteur, 25 Rue du Dr. Roux, 75724 Paris cedex 15, France.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Nov 1) 277 (44) 41657-66.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 20021108
Last Updated on STN: 20030118
Entered Medline: 20030117

L7 ANSWER 61 OF 138 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AB We present the complete genome sequence of Yersinia pestis KIM, the etiologic agent of bubonic and pneumonic plague. The strain KIM, biovar Mediaevalis, is associated with the second pandemic, including the Black Death. The 4.6-Mb genome encodes 4,198 open reading frames (ORFs). The origin, terminus, and most genes encoding DNA replication proteins are similar to those of Escherichia coli K-12. The KIM genome sequence was compared with that of Y. pestis CO92, biovar Orientalis, revealing homologous sequences but a remarkable amount of genome rearrangement for strains so closely related. The differences appear to result from multiple inversions of genome segments at insertion sequences, in a manner consistent with present knowledge of replication and recombination. There are few differences attributable to horizontal transfer. The KIM and E. coli K-12 genome proteins were also compared, exposing surprising amounts of locally colinear "backbone," or synteny, that is not discernible at the nucleotide level. Nearly 54% of KIM ORFs are significantly similar to K-12 proteins, with conserved housekeeping functions. However, a number of E. coli pathways and **transport systems** and at least one global regulator were not found, reflecting differences in lifestyle between them. In KIM-specific islands, new genes encode candidate pathogenicity proteins, including iron **transport systems**, putative adhesins, toxins, and fimbriae.
AN 2002:634284 SCISEARCH
GA The Genuine Article (R) Number: 577KF
TI Genome sequence of Yersinia pestis KIM
AU Deng W; Burland V; Plunkett G; Boutin A; Mayhew G F; Liss P; Perna N T; Rose D J; Mau B; Zhou S G; Schwartz D C; Fetherston J D; Lindler L E; Brubaker R R; Plano G V; Straley S C; McDonough K A; Nilles M L; Matson J S; Blattner F R (Reprint); Perry R D
CS Univ Wisconsin, Genet Lab, 445 Henry Mall, Madison, WI 53706 USA (Reprint); Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Genome Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Walter Reed Army Inst Res, Div Communicable Dis & Immunol, Dept Bacterial Dis, Washington, DC 20307 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33176 USA; Wadsworth Ctr, David Axelrod Inst, Albany, NY 12201 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Microbiol & Immunol, Grand Forks, ND 58202 USA
CYA USA
SO JOURNAL OF BACTERIOLOGY, (AUG 2002) Vol. 184, No. 16, pp. 4601-4611.
Publisher: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA.
ISSN: 0021-9193.
DT Article; Journal

LA English
REC Reference Count: 47
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

L7 ANSWER 62 OF 138 USPATFULL
AB A novel subset of monocyte-derived dendritic cells are provided. Methods for producing these monocyte-derived dendritic cells and compositions comprising the dendritic cells of the invention are also provided. Methods for inducing an immune response to an antigen of interest using the dendritic cells of the invention are provided. Also provided are methods for therapeutically or prophylactically treating a disease in a subject suffering from the disease using the dendritic cells.
AN 2001:170889 USPATFULL
TI Monocyte-derived dendritic cell subsets
IN Punnonen, Juha, Palo Alto, CA, United States
Chang, Chia-Chun J., Los Gatos, CA, United States
PI US 2001026937 A1 20011004
AI US 2001-760388 A1 20010110 (9)
PRAI US 2000-175552P 20000111 (60)
US 2000-181957P 20000210 (60)
DT Utility
FS APPLICATION
LREP LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3189

L7 ANSWER 63 OF 138 USPATFULL
AB The present invention provides a process for identifying a chemical compound which specifically binds to a rat or human 5-HT.sub.4 receptor. The invention also provides a process involving competitive binding for identifying a chemical compound which specifically binds to a rat or human 5-HT.sub.4 receptor. The invention provides for a process for determining whether a chemical compound specifically binds to and activates a rat or human 5-HT.sub.4 receptor. The invention additionally provides for a process for determining whether a chemical compound specifically binds to and inhibits activation of a rat or human 5-HT.sub.4 receptor.
AN 2001:231148 USPATFULL
TI Uses of the 5-HT4 receptor
IN Gerald, Christophe, Ridgewood, NJ, United States
Hartig, Paul R., Pennington, NJ, United States
Branchek, Theresa, Teaneck, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 6331401 B1 20011218
AI US 1998-328314 19980403 (9)
RLI Division of Ser. No. US 446822, now patented, Pat. No. US 5766879
Continuation-in-part of Ser. No. US 1992-996772, filed on 24 Dec 1992, now patented, Pat. No. US 5472866, issued on 5 Dec 1995
DT Utility
FS GRANTED
EXNAM Primary Examiner: Allen, Marianne P.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 2331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 64 OF 138 USPATFULL
AB This invention provides various methods for identifying one or more

genetic alterations in a sample polynucleotide strand.
AN 2001:167898 USPATFULL
TI Method for detecting and identifying mutations
IN Stefano, James E., Hopkinton, MA, United States
PA Genzyme Corporation, Framingham, MA, United States (U.S. corporation)
PI US 6297010 B1 20011002
AI US 1998-16542 19980130 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Arthur, Lisa B.; Assistant Examiner: Souaya, Jehanne
LREP Konski, Antoinette F., Dugan, Deborah A.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 65 OF 138 USPATFULL
AB Multimolecular devices and drug delivery systems prepared from synthetic heteropolymers, heteropolymeric discrete structures, multivalent heteropolymeric hybrid structures, aptameric multimolecular devices, multivalent imprints, tethered specific recognition devices, paired specific recognition devices, nonaptameric multimolecular devices and immobilized multimolecular structures are provided, including molecular adsorbents and multimolecular adherents, adhesives, transducers, switches, sensors and delivery systems. Methods for selecting single synthetic nucleotides, shape-specific probes and specifically attractive surfaces for use in these multimolecular devices are also provided. In addition, paired nucleotide-nonnucleotide mapping libraries for transposition of selected populations of selected nonoligonucleotide molecules into selected populations of replicatable nucleotide sequences are described.
AN 2001:152673 USPATFULL
TI Methods for detecting and identifying single molecules
IN Cubicciotti, Roger S., Montclair, NJ, United States
PA Molecular Machines, Inc., Montclair, NJ, United States (U.S. corporation)
PI US 6287765 B1 20010911
AI US 1998-81930 19980520 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Licata & Tyrrell P.C.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 66 OF 138 USPATFULL
AB A system and method for processing a lipid membrane bound structure, the method comprising the steps of providing the structure to be processed in a liquid medium; and beating the liquid medium containing the structure at a rate and through a range sufficient to cause a discrete phase transition in at least one of the membranes, such that the membranes fuse. The method may be used to fuse the structure with another structure, or to reduce the integrity of the structure. The apparatus atomizes a medium containing the structure into small droplets and subjects them to an environment containing steam vapor while moving at high velocity, to rapidly increase the droplet temperature to the steam temperature by release of the latent heat of vaporization.
AN 2001:136415 USPATFULL
TI Rapid thermal cycle processing methods and apparatus
IN Grae, Joel B., Peekskill, NY, United States

PA IB2, LLC, New York, NY, United States (U.S. corporation)
PI US 6277610 B1 20010821
WO 9915638 19990401
AI US 2000-508889 20000317 (9)
WO 1998-US19815 19980923
20000317 PCT 371 date
20000317 PCT 102(e) date
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon P.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 2330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 67 OF 138 USPATFULL
AB A method is described for detecting, selecting, and cloning agents that degrade DNA or promote DNA degradation. The method utilizes extra-chromosomal replicons whose replication is dependent on degradation of a host cell's DNA to screen for agents leading to degradation of cellular DNA. An agent which promotes degradation of a host cell's DNA enables the replicons to replicate, which signals the presence of agents that promote the cellular DNA degradation and allows for the isolation and amplification of such agents.
AN 2001:121246 USPATFULL
TI Methods for detecting, selecting and cloning agents that degrade or promote degradation of DNA
IN Mattson, Thomas L., 20220 Tidewinds Way, Germantown, MD, United States 20874
PI US 6268139 B1 20010731
AI US 1999-261764 19990303 (9)
PRAI US 1998-76657P 19980303 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Whisenant, Ethan
LREP Foley & Lardner
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 68 OF 138 USPATFULL
AB The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.
AN 2001:117155 USPATFULL
TI Insulin receptor tyrosine kinase substrate
IN Hillman, Jennifer L., Mountain View, CA, United States
Lal, Preeti, Sunnyvale, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PA Incyte Genomics, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 6265550 B1 20010724
AI US 1999-270117 19990315 (9)
RLI Division of Ser. No. US 1997-878563, filed on 19 Jun 1997, now patented, Pat. No. US 5891674
DT Utility
FS GRANTED
EXNAM Primary Examiner: Eyler, Yvonne; Assistant Examiner: Lazar-Wesley, Eliane

LREP Incyte Genomics, Inc.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 69 OF 138 USPATFULL
AB The present invention is directed to mutants of the jellyfish Aequorea victoria green fluorescent protein (GFP) having at least 5 and preferably greater than 20 times the specific green fluorescence of the wild type protein. In other embodiments, the invention comprises mutant blue fluorescent proteins (BFPs) that emit an enhanced blue fluorescence. The invention also encompasses the expression of nucleic acids that encode a mutant GFP or BFP in a wide variety of engineered host cells, and the isolation of engineered proteins having increased fluorescent activity. The novel mutants of the present invention allow for a significantly more sensitive detection of fluorescence in engineered host cells than is possible with GFP or with its known mutants. Thus, the mutant fluorescent proteins provided herein can be used as sensitive reporter molecules to detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or BFP mutants, or of chimeric proteins comprising GFP or BFP mutants fused to a regulatory sequence or to a second protein sequence.
AN 2001:117153 USPATFULL
TI Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
IN Pavlakis, George N., Rockville, MD, United States
Gaitanaris, George A., Frederick, MD, United States
Stauber, Roland H., Erlangen, Germany, Federal Republic of
Vournakis, John N., Charleston, SC, United States
PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Rockville, MD, United States (U.S. government)
PI US 6265548 B1 20010724
AI US 2000-503222 20000211 (9)
RLI Division of Ser. No. US 1996-646538, filed on 8 May 1996, now patented, Pat. No. US 6027881
DT Utility
FS GRANTED
EXNAM Primary Examiner: Slobodyansky, Elizabeth
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 7
DRWN No Drawings
LN.CNT 2115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 70 OF 138 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2001:86448 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Lee, May, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
Renau, Thomas, Santa Clara, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6245746 B1 20010612
AI US 1998-20001 19980204 (9)

RLI Continuation-in-part of Ser. No. US 1998-12363, filed on 23 Jan 1998, now patented, Pat. No. US 6114310
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 71 OF 138 USPATFULL
AB The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
AN 2001:43711 USPATFULL
TI Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IN Dan, Michael D., Scarborough, Canada
Maiti, Pradip K., Winnipeg, Canada
Kaplan, Howard A., Winnipeg, Canada
PA Viventia Biotech, Inc., Toronto, Canada (non-U.S. corporation)
PI US 6207153 B1 20010327
AI US 1997-862124 19970522 (8)
RLI Continuation-in-part of Ser. No. US 1996-657449, filed on 22 May 1996, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Bansal, Geetha P.
LREP Frommer Lawrence & Haug LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 3359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 72 OF 138 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2001:40493 USPATFULL
TI Peptidomimetic efflux pump inhibitors
IN Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
She, Miles, Oakland, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6204279 B1 20010320
AI US 1998-89734 19980603 (9)
DT Utility

FS Granted
EXNAM Primary Examiner: Lee, Howard C.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 73 OF 138 USPATFULL
AB A method of altering an expression of a gene product in cells or an organism, comprising orally administering glutathione in an effective amount and under such conditions to alter a redox potential in the cells. The gene expression may be sensitive to redox potential through one or more of a process of induction, transcription, translation, post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.
AN 2001:40462 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Fairfield, CT, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6204248 B1 20010320
AI US 1999-457642 19991209 (9)
RLI Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 74 OF 138 USPATFULL
AB The present invention provides a number of screening methods for evaluating compounds capable of suppressing cytokine production either in vitro or in vivo. The methods generally involve stimulating the production of a cytokine in a cell, exposing a portion of the cells to a putative cytokine modulating agent and determining subsequent levels of cytokine production in the cells. Additionally, the present invention provides certain compounds identified by this method.
AN 2001:25458 USPATFULL
TI Methods for treating inflammatory conditions
IN Mak, Vivien H. W., Menlo Park, CA, United States
PA Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PI US 6190691 B1 20010220
AI US 1998-97440 19980615 (9)
RLI Continuation of Ser. No. US 1995-463819, filed on 5 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-400234, filed on 3 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1994-271287, filed on 6 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Brouillette, D. Gabrielle
LREP Seidman, Stephanie L.Heller Ehrman White & McAuliffe

CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 5240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 75 OF 138 USPATFULL
AB Methods for obtaining surface expression of a desired protein or polypeptide in Gram-positive host organisms are provided. In addition, vectors useful in such methods as well as Gram-positive host organisms transformed with such vectors are disclosed.
AN 2001:25429 USPATFULL
TI Materials and methods relating to the attachment and display of substances on cell surfaces
IN Steidler, Lothar, Ghent, Belgium
Remaut, Erik, Ghent, Belgium
Wells, Jeremy Mark, Cambridge, United Kingdom
PA Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) vzw, Zwijnaarde, Belgium (non-U.S. corporation)
PI US 6190662 B1 20010220
AI US 1998-36609 19980306 (9)
RLI Continuation of Ser. No. WO 1996-GB2195, filed on 6 Sep 1996
PRAI GB 1995-18323 19950907
DT Utility
FS Granted
EXNAM Primary Examiner: Navarro, Albert
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 76 OF 138 USPATFULL
AB The present invention relates to mouse and human cDNAs for a gene family designated Nramp (natural resistance-associated macrophage protein), involved in macrophage function and responsible for the natural resistance to infection with intracellular parasites, and to the isolation of Nramp sequences from other animal sources. The nucleotide sequences of the mouse and human cDNAs are disclosed, as are the amino sequences of the encoded products. The cDNAs can be expressed in expression constructs. These expression constructs and the proteins produced therefrom can be used for a variety of purposes including diagnostic and therapeutic methods.
AN 2001:18278 USPATFULL
TI DNA sequences that encode a natural resistance to infection with intracellular parasites
IN Gros, Philippe, St-Lambert, Canada
Skamene, Emil, Montreal, Canada
Malo, Danielle, Montreal, Canada
Vidal, Silvia, Ottawa, Canada
PA McGill University, Montreal, Canada (non-U.S. corporation)
PI US 6184031 B1 20010206
WO 9513371 19950518
AI US 1996-637823 19960508 (8)
WO 1994-CA621 19941108
19960508 PCT 371 date
19960508 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-235405, filed on 28 Apr 1994, now abandoned Continuation-in-part of Ser. No. US 1993-148481, filed on 8 Nov 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Myers, Carla J.

LREP Klauber & Jackson
CLMN Number of Claims: 31
ECL Exemplary Claim: 1,3,4
DRWN 27 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 77 OF 138 USPATFULL
AB The present invention is directed to oligonucleotides used as amplification primers and assay probes for specific and sensitive for virulent strains of V. vulnificus. The target sequence of the probes and primers according to present invention is a capsular polysaccharide (CPS) transport gene (wza) of V. vulnificus. These probes can detect wza DNA or RNA in an unknown sample suspected to have pathogenic strains of V. vulnificus including human, animal, or environmental samples. The invention is also directed to in vitro-expressed protein from the cloned wza for production of polyclonal or monoclonal antibody that is specific for the wza gene product and will detect the V. vulnificus Wza protein in a sample comprising unknown protein.
AN 2001:18221 USPATFULL
TI Vibrio vulnificus molecular probes, antibodies, and proteins
IN Wright, Anita C., Woodstock, MD, United States
Powell, Jan L., Baltimore, MD, United States
Morris, Jr., J. Glenn, Baltimore, MD, United States
PA UMBI - University of Maryland Biotechnology Institute, Baltimore, MD, United States (U.S. corporation)
PI US 6183973 B1 20010206
AI US 1998-205283 19981204 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US1467, filed on 19 Jun 1998
PRAI US 1997-50243P 19970619 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Lu, Frank
LREP Blank Rome Comisky & McCauley LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 78 OF 138 USPATFULL
AB The present invention provides isolated nucleic acids encoding human EHOC-1 protein and isolated receptor proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing, antibodies that specifically bind to invention polypeptides and compositions containing, as well as transgenic non-human mammals that express the invention protein.
AN 2000:174806 USPATFULL
TI Chromosome 21 gene marker, compositions and methods using same
IN Korenberg, Julie R., Los Angeles, CA, United States
Yamakawa, Kazuhiro, Los Angeles, CA, United States
PA Cedar-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)
PI US 6166180 20001226
AI US 1998-48887 19980326 (9)
RLI Division of Ser. No. US 1994-337690, filed on 9 Nov 1994, now patented, Pat. No. US 5773268
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 6

ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 79 OF 138 USPATFULL
AB The present invention contemplates chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor-donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore, and methods using the photonic structures.
AN 2000:170829 USPATFULL
TI Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
IN Heller, Michael J., Encinitas, CA, United States
PA Nanogen, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6162603 20001219
AI US 1998-123638 19980728 (9)
RLI Continuation of Ser. No. US 1996-703601, filed on 23 Aug 1996, now patented, Pat. No. US 5899489 which is a continuation of Ser. No. US 1994-250951, filed on 27 May 1994, now patented, Pat. No. US 5532129 which is a continuation of Ser. No. US 232233
DT Utility
FS Granted
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Lyon & Lyon LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 80 OF 138 USPATFULL
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.
AN 2000:167548 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corporation, Elmsford, NY, United States (U.S. corporation)
PI US 6159500 20001212
AI US 1997-2100 19971231 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 81 OF 138 USPATFULL
AB A novel gene encoding a 37 kDa outer membrane protein from Campylobacter

coli· M275 has been cloned and sequenced. This protein has been named CadF and is expressed in a large number of clinical isolates of Campylobacter species. The invention also provides assays for detecting the presence of pathogenic Campylobacter species based on the antibody-based detection of CadF, or the polymerase chain reaction (PCR)-based amplification of a segment of the C. coli cadF gene.
AN 2000:164305 USPATFULL
TI Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
IN Konkel, Michael E., Pullman, WA, United States
Garvis, Steven G., Pullman, WA, United States
PA Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)
PI US 6156546 20001205
AI US 1998-80025 19980515 (9)
PRAI US 1997-46763P 19970516 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Fredman, Jeffrey; Assistant Examiner: Einsmann, Juliet C.
LREP Christensen O'Connor Johnson & Kindness PLLC
CLMN Number of Claims: 14
ECL Exemplary Claim: 14
DRWN No Drawings
LN.CNT 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 82 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
AN 2000:164277 USPATFULL
TI Methods of using DNA encoding human alpha 1 adrenergic receptors
IN Bard, Jonathan A., Doylestown, PA, United States
Weinshank, Richard L., Teaneck, NJ, United States
Forray, Carlos C., Paramus, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 6156518 20001205
AI US 1999-474551 19991229 (9)
RLI Continuation of Ser. No. US 1998-206899, filed on 7 Dec 1998, now patented, Pat. No. US 6083705 which is a division of Ser. No. US 406855
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Wang, Andrew
LREP White, John P., Dunham, Christopher C.Cooper & Dunham LLP
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 3821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 83 OF 138 USPATFULL
AB The invention features a method for identifying compositions which modulate the activity of a Na.sup.+ -dependent nucleoside transport

polypeptide. This invention also features isolated DNA encoding the transport polypeptide, a method for recombinantly producing the transport polypeptide, antibodies which specifically bind to the polypeptide and polynucleotide sequences which specifically hybridize to polynucleotide encoding the transport polypeptide.
AN 2000:161136 USPATFULL
TI cDNA encoding nucleoside transporter
IN Young, James D., Edmonton, Canada
Cass, Carol E., Edmonton, Canada
PA University of Alberta, Canada (non-U.S. corporation)
PI US 6153740 20001128
AI US 1997-800291 19970213 (8)
RLI Continuation-in-part of Ser. No. US 1995-499314, filed on 7 Jul 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ulm, John
LREP Fish & Richardson P.C.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 2336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 84 OF 138 USPATFULL
AB This invention provides an immunoenhancement or immune-potentiation therapy comprising administration of potassium, insulin, glucose and, optionally, thyroid, a cholinergic agent and bicarbonate. Therapeutic compositions comprising the above components in appropriate dosages are also provided.
AN 2000:150137 USPATFULL
TI Pharmaceutical composition and method for immunoenhancement therapy
IN Hill, Albert Fay, Denver, CO, United States
PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)
PI US 6143717 20001107
AI US 1998-198354 19981124 (9)
RLI Division of Ser. No. US 1997-790683, filed on 28 Jan 1997, now patented, Pat. No. US 5840770 which is a continuation of Ser. No. US 1995-426088, filed on 21 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US 5449522
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Greenlee, Winner and Sullivan, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 85 OF 138 USPATFULL
AB Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
AN 2000:117691 USPATFULL
TI Efflux pump inhibitors
IN Chamberland, Suzanne, Los Gatos, CA, United States
Lee, May, Los Altos, CA, United States
Leger, Roger, Mountain View, CA, United States
Lee, Ving J., Los Altos, CA, United States
Renau, Thomas, Santa Clara, CA, United States
Zhang, Zhijia J., Foster City, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S.

corporation)
PI US 6114310 20000905
AI US 1998-12363 19980123 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E
LREP Lyon & Lyon LLP
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 86 OF 138 USPATFULL
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
AN 2000:102075 USPATFULL
TI Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IN Fowlkes, Dana Merriman, New York, NY, United States
Broach, Jim, New York, NY, United States
Manfredi, John, New York, NY, United States
Klein, Christine, New York, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, Palisades, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 6100042 20000808
AI US 1994-322137 19941013 (8)
RLI Continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ulm, John
LREP Lahive & Cockfield, LLP, Lauro, Esq., Peter C., Kara, Catherine J.
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 6899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 87 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.
AN 2000:84046 USPATFULL

TI DNA encoding human .alpha. 1 adrenergic receptors and uses thereof
IN Bard, Jonathon A., Wyckoff, NJ, United States
Weinshank, Richard L., New York, NY, United States
Forray, Carlos, Paramus, NJ, United States
PA Synaptic Pharmaceuticals Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 6083705 20000704
AI US 1998-206899 19981207 (9)
RLI Division of Ser. No. US 406855
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Wang, Andrew
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 4093
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 88 OF 138 USPATFULL
AB The present invention is directed to mutants of the jellyfish Aequorea victoria green fluorescent protein (GFP) having at least 5 and preferably greater than 20 times the specific green fluorescence of the wild type protein. In other embodiments, the invention comprises mutant blue fluorescent proteins (BFPs) that emit an enhanced blue fluorescence. The invention also encompasses the expression of nucleic acids that encode a mutant GFP or BFP in a wide variety of engineered host cells, and the isolation of engineered proteins having increased fluorescent activity. The novel mutants of the present invention allow for a significantly more sensitive detection of fluorescence in engineered host cells than is possible with GFP or with its known mutants. Thus, the mutant fluorescent proteins provided herein can be used as sensitive reporter molecules to detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or BFP mutants, or of chimeric proteins comprising GFP or BFP mutants fused to a regulatory sequence or to a second protein sequence.
AN 2000:21375 USPATFULL
TI Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
IN Pavlakis, George N., Rockville, MD, United States
Gaitanaris, George A., Gaithersburg, MD, United States
Stauber, Roland H., Frederick, MD, United States
Vournakis, John N., Hanover, NH, United States
PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6027881 20000222
AI US 1996-646538 19960508 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Slobodyansky, Elizabeth
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 89 OF 138 USPATFULL
AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 2000:7062 USPATFULL

TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockfeller University, New York, NY, United States (U.S. corporation)
PI US 6015560 20000118
AI US 1995-465966 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation of Ser. No. WO 1992-US3725, filed on 4 May 1992 which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Minnifield, Nita
LREP Klauber & Jackson
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 90 OF 138 USPATFULL
AB This invention provides isolated nucleic acid molecules encoding a human and a rat Y2 receptor, an isolated protein which is a human or rat Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human or rat Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human or rat Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human or rat Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human or rat Y2 receptor, pharmaceutical compounds related to human or rat Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human or rat Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human or rat Y2 receptor.
AN 1999:150937 USPATFULL
TI Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding
IN Gerald, Christophe, Ridgewood, NJ, United States
Walker, Mary W., Elmwood Park, NJ, United States
Branchek, Theresa, Teaneck, NJ, United States
Weinshank, Richard L., Teaneck, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5989834 19991123
WO 9521245 19950810
AI US 1996-687355 19961126 (8)
WO 1995-US1469 19950203
19961126 PCT 371 date
19961126 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-192288, filed on 3 Feb 1994, now patented, Pat. No. US 5545549
DT Utility
FS Granted
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Gucker, Stephen
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 3800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 91 OF 138 USPATFULL
AB Methods are provided for screening for inhibitors of microbial efflux pumps including those which export antibiotics. The screening methods are based on the increase in the intracellular concentration of a compound, such as an antibiotic, when the bacterial cells are contacted with an efflux pump inhibitor. In addition, this invention provides pharmaceutical compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions.
AN 1999:150935 USPATFULL
TI Method for screening for non-tetracycline efflux pump inhibitors
IN Trias, Joaquim, San Mateo, CA, United States
Chamberland, Suzanne, Los Gatos, CA, United States
Hecker, Scott J., Los Gatos, CA, United States
Lee, Ving J., Los Altos, CA, United States
PA Microcide Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5989832 19991123
AI US 1995-427088 19950421 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Pak, Michael
LREP Lyon & Lyon LLP
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 92 OF 138 USPATFULL
AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 1999:128131 USPATFULL
TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5968512 19991019
AI US 1995-465965 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation of Ser. No. WO 1992-US3725, filed on 4 May 1992 which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Minnifield, Nita
LREP Klauber & Jackson
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 93 OF 138 USPATFULL
AB The present invention provides a number of screening methods for evaluatiing compounds capable of suppressing cytokine production either in vitro or in vivo. The methods generally involve stimulating the production of a cytokine in a cell, exposing a portion of the cells to a putative cytokine modulating agent and determining subsequent levels of cytokine production in the cells. Additionally, the present invention provides certain compounds identified by this method.
AN 1999:121379 USPATFULL

TI Screening methods for cytokine inhibitors
IN Mak, Vivian, Menlo Park, CA, United States
PA Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PI US 5962477 19991005
AI US 1998-97441 19980615 (9)
RLI Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-271287, filed on 6 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.
LREP Seidman, Stephanie L.Heller Ehrman White & McAuliffe
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 5138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 94 OF 138 USPATFULL
AB Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described.
AN 1999:88796 USPATFULL
TI Peptides which inhibit adhesion between leukocytes and endothelial cells
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5932217 19990803
AI US 1994-348353 19941130 (8)
RLI Continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 140136
DT Utility
FS Granted
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark
LREP Klauber & Jackson
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 3167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 95 OF 138 USPATFULL
AB A composition comprising an immobilized biological membrane is provided. The functional immobilized biological membrane consists of a support structure, a metal layered onto a surface of the support structure, an alkanethiol monolayer assembled onto the metal, and a biological membrane deposited on the alkanethiol monolayer. Also provided is a method of producing the immobilized biological membrane, wherein the method involves contacting an alkanethiol with a metal surface of a support structure in forming an alkanethiol monolayer assembled onto the metal, and depositing a biological membrane onto the alkanethiol monolayer such that the biological membrane becomes associated with the alkanethiol monolayer. Uses of the biological membrane include as a sensing indicator in a biosensor, as an adsorbent in a chromatography system, and as a coating for medical devices.
AN 1999:75433 USPATFULL
TI Immobilized biological membranes
IN Hui, Sek Wen, Williamsville, NY, United States
Plant, Anne, Arlington, VA, United States
Rao, Madhusudhana, Hyderabad, India

PA Health Research Inc., Buffalo, NY, United States (U.S. corporation)
Government of the USA, Nat'l Institute of Standards, Washington, DC, United States (U.S. government)
PI US 5919576 19990706
AI US 1997-975842 19971121 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Hodgson, Russ, Andrews, Woods & Goodyear, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 96 OF 138 USPATFULL
AB A growth supplement for bacterial media is used to induce and/or maintain differentiation and viability of bacterial cell cultures. The supplement contains about 10 mM to about 100 mM of a sugar, an amino acid or mixtures thereof. When the media used does not contain iron and reducing agents, such as sodium thiosulfate, these are included in the supplement. The reducing agent is present preferably at about 20 to about 40 mM. The addition of this supplement results in flagellation of aflagellate variants of Salmonella and hyperflagellation of variants of Salmonella which are flagellated.
AN 1999:56414 USPATFULL
TI Complex growth supplement for maintenance of bacterial cell viability and induction of bacterial cell differentiation
IN Petter, Jean Guard, Athens, GA, United States
Ingram, Kim D., Watkinsville, GA, United States
PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)
PI US 5902742 19990511
AI US 1996-649501 19960517 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Lankford, Jr., Leon B.; Assistant Examiner: Tate, Christopher R.
LREP Silverstein, M. Howard, Fado, John, Poulos, Gail E.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 97 OF 138 USPATFULL
AB The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.
AN 1999:43751 USPATFULL
TI Genes from the 20Q13 amplicon and their uses
IN Gray, Joe, San Francisco, CA, United States
Collins, Colin, San Rafael, CA, United States
Hwang, Soo-in, Berkeley, CA, United States
Godfrey, Tony, San Francisco, CA, United States
Kowbel, David, Oakland, CA, United States
Rommens, Johanna, Toronto, Canada
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
The Hospital for Sick Children, Toronto, Canada (non-U.S. corporation)
PI US 5892010 19990406
AI US 1996-680395 19960715 (8)

DT Utility
FS Granted
EXNAM Primary Examiner: Scheiner, Toni R.; Assistant Examiner: Johnson, Nancy A.
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 98 OF 138 USPATFULL
AB The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.
AN 1999:43422 USPATFULL
TI Insulin receptor tyrosine kinase substrate
IN Hillman, Jennifer L., Mountain View, CA, United States
Lal, Preeti, Sunnyvale, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5891674 19990406
AI US 1997-878563 19970619 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Lazar-Wesley, Eliane
LREP Price, Esq., Leanne C., Billings, Esq., Lucy J.Incyte Pharmaceuticals, Inc.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 99 OF 138 USPATFULL
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
AN 1999:27415 USPATFULL
TI Yeast cells engineered to produce pheromone system protein surrogates and uses therefor
IN Fowlkes, Dana M., Chapel Hill, NC, United States
Broach, Jim, Princeton, NJ, United States
Manfredi, John, Ossining, NY, United States
Klein, Christine, Ossining, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, South Nyack, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5876951 19990302
AI US 1995-461598 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993,

now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Yucel, Irem
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara, Catherine J.
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 6645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 100 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
AN 1999:7296 USPATFULL
TI DNA endoding human alpha 1 adrenergic receptors
IN Bard, Jonathan A., Wyckoff, NJ, United States
Weinshank, Richard L., New York, NY, United States
Forray, Carlos, Paramus, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5861309 19990119
WO 9408040 19940414
AI US 1995-406855 19950821 (8)
WO 1993-US9187 19930924
19950821 PCT 371 date
19950821 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-952798, filed on 25 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.; Assistant Examiner: Wang, Andrew
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 3297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 101 OF 138 USPATFULL
AB The present invention provides an oligonucleotide (aarC) which encodes a novel bacterial polypeptide (AarC) that is essential for the viability of **bacteria**. The invention provides recombinant expression vectors comprising the nucleotide sequence encoding AarC, as well as host cells containing these expression vectors. Further provided herein are methods for screening **bacteria** which contain aarC or variants or homologs thereof. Also provided are methods for using the aarC oligonucleotide sequence to screen antimicrobials which target AarC activity in gram negative and gram positive **bacteria**. Additionally, the invention provides for the use of aarC in diagnostic assays which utilize the aarC oligonucleotide to hybridize with nucleic acid sequences encoding AarC as well as with AarC mRNA. The invention further describes monoclonal and polyclonal AarC antibodies and their use in diagnostic assays for the detection of **bacteria** which express AarC.

AN 1999:4040 USPATFULL
TI Methods for screening for antimicrobials utilizing AarC and compositions thereof
IN Rather, Philip N., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 5858367 19990112
AI US 1997-827190 19970327 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 102 OF 138 USPATFULL
AB The invention relates to nucleic acid-binding oligomers possessing C-branching of the general formula (I) ##STR1## and to the corresponding monomers, whose radicals have the meaning given in the description, and to their use as medicaments or diagnostic aids.
AN 1998:157491 USPATFULL
TI Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
IN Lobberding, Antonius, Wuppertal, Germany, Federal Republic of
Mielke, Burkhard, Leverkusen, Germany, Federal Republic of
Schwemler, Christoph, Leichlingen, Germany, Federal Republic of
Schwenner, Eckhard, Wuppertal, Germany, Federal Republic of
Stropp, Udo, Haan, Germany, Federal Republic of
Springer, Wolfgang, Wuppertal, Germany, Federal Republic of
Kretschmer, Axel, Bergisch Gladbach, Germany, Federal Republic of
Potter, Thorsten, Koln, Germany, Federal Republic of
PA Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)
PI US 5849893 19981215
AI US 1996-719048 19960924 (8)
RLI Division of Ser. No. US 1994-300910, filed on 6 Sep 1994
PRAI DE 1993-4331011 19930913
DT Utility
FS Granted
EXNAM Primary Examiner: Houtteman, Scott W.
LREP Sprung Kramer Schaefer & Briscoe
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 103 OF 138 USPATFULL
AB The present invention contemplates chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor--donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore, and methods using the photonic structures.
AN 1998:157107 USPATFULL
TI Hybridization of polynucleotides conjugated with chromophores and

fluorophores to generate donor-to-donor energy transfer system
IN Heller, Michael J., Encinitas, CA, United States
PA Nanogen, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5849489 19981215
AI US 1996-703601 19960823 (8)
RLI Continuation of Ser. No. US 1994-232233, filed on 5 May 1994, now patented, Pat. No. US 5565322, issued on 6 Nov 1992 which is a continuation-in-part of Ser. No. US 1994-250951, filed on 27 May 1994, now patented, Pat. No. US 5532129 which is a continuation of Ser. No. US 1991-790262, filed on 7 Nov 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Fredman, Jeffrey
LREP Lyon & Lyon LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1833
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 104 OF 138 USPATFULL
AB The present invention provides polynucleotides which identify and encode a novel human proteolipid (PLHu). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PLHu. The invention also provides for the use of substantially purified PLHu and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of PLHu. Additionally, the invention provides for the use of antisense molecules to PLHu in the treatment of diseases associated with the expression of PLHu. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding PLHu and antibodies which specifically bind to the protein.
AN 1998:150730 USPATFULL
TI DNA encoding a novel human proteolipid
IN Au-Young, Janice, Berkeley, CA, United States
Bandman, Olga, Mountain View, CA, United States
Goli, Surya K., Sunnyvale, CA, United States
Hillman, Jennifer L., San Jose, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5843714 19981201
AI US 1996-695736 19960726 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Walsh, Stephen; Assistant Examiner: Pak, Michael D.
LREP Billings, Lucy J.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 105 OF 138 USPATFULL
AB The invention features a Salmonella cell the virulence of which is attenuated by a deletion of a portion of the PhoQ gene and Salmonella cells having a deletion of the PhoQ gene and a deletion of the PhoP gene. The invention also features vaccines comprising such **bacteria**.
AN 1998:150449 USPATFULL
TI Salmonella vaccines
IN Miller, Samuel I., Seattle, WA, United States
Mekalanos, John J., Cambridge, MA, United States

PA The General Hospital Corporation, Boston, MS, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MS, United States (U.S. corporation)
PI US 5843426 19981201
AI US 1995-565861 19951201 (8)
RLI Continuation-in-part of Ser. No. US 1994-271354, filed on 6 Jul 1994, now patented, Pat. No. US 5695983 which is a continuation-in-part of Ser. No. US 1993-90526, filed on 9 Jul 1993, now patented, Pat. No. US 5599537 which is a continuation-in-part of Ser. No. US 1990-629602, filed on 18 Dec 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuvader, John L.; Assistant Examiner: Brusca, John S.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 4505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 106 OF 138 USPATFULL
AB This invention provides an immunoenhancement or immune-potentiation therapy comprising administration of potassium, insulin, glucose and, optionally, thyroid, a cholinergic agent and bicarbonate. Therapeutic compositions comprising the above components in appropriate dosages are also provided.
AN 1998:147485 USPATFULL
TI Method of killing tumor cells
IN Hill, Albert Fay, Denver, CO, United States
PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)
PI US 5840770 19981124
AI US 1997-790683 19970128 (8)
RLI Continuation of Ser. No. US 1995-426088, filed on 21 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US 5449522
DT Utility
FS Granted
EXNAM Primary Examiner: Harrison, Robert H.
LREP Greenlee, Winner and Sullivan, P.C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 107 OF 138 USPATFULL
AB Peptides and antibodies which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents and a method of increasing the permeability of the blood-brain barrier using an antibody to the Arg-Gly-Asp (RGD) region of filamentous hemagglutinin (FHA) are described.
AN 1998:95235 USPATFULL
TI Antibody recognizing endothelial cell ligand for leukocyte CR3
IN Tuomanen, Elaine, New York, NY, United States
Masure, H. Robert, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5792457 19980811
AI US 1995-465929 19950606 (8)
RLI Division of Ser. No. US 1994-348353, filed on 30 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-247572, filed on 23 May 1994,

now abandoned which is a continuation-in-part of Ser. No. US 1991-695613, filed on 3 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Krikorian, Jacqueline G.
LREP Klauber & Jackson
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 2578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 108 OF 138 USPATFULL
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
AN 1998:91815 USPATFULL
TI Yeast cells engincered to produce pheromone system protein surrogates, and uses therefor
IN Fowlkes, Dana M., Chapel Hill, NC, United States
Broach, Jim, Princeton, NJ, United States
Manfredi, John, Ossining, NY, United States
Klein, Christine, Ossining, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, South Nyack, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5789184 19980804
AI US 1995-464531 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Yucel, Irem
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara, Catherine J.
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 6731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 109 OF 138 USPATFULL
AB The present invention provides isolated nucleic acids encoding human EHOC-1 protein and isolated receptor proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing, antibodies that specifically bind to invention polypeptides and compositions containing, as well as transgenic non-human mammals that express the invention protein.
AN 1998:75417 USPATFULL
TI Chromosome 21 gene marker, compositions and methods using same
IN Korenberg, Julie R., Los Angeles, CA, United States
Yamakawa, Kazuhiro, Los Angeles, CA, United States

PA Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)
PI US 5773268 19980630
AI US 1994-337690 19941109 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Low, Christopher S. F.
LREP Campbell & Flores LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1,19
DRWN 4 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 110 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, an isolated protein which is a mammalian 5-HT.sub.4 receptor, an isolated protein which is a human 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4 receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4 receptor, pharmaceutical compounds related to the human 5-HT.sub.4 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT.sub.4 receptor.
AN 1998:68804 USPATFULL
TI DNA encoding 5-HT.sub.4 serotonin receptors and uses thereof
IN Gerald, Christophe, Ridgewood, NJ, United States
Hartig, Paul R., Pennington, NJ, United States
Branchek, Theresa, Teaneck, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5766879 19980616
WO 9414957 19940707
AI US 1995-446822 19950731 (8)
WO 1993-US12586 19931222
19950731 PCT 371 date
19950731 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-996772, filed on 24 Dec 1992, now patented, Pat. No. US 5472866, issued on 5 Dec 1995
DT Utility
FS Granted
EXNAM Primary Examiner: Allen, Marianne P.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 2660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 111 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.
AN 1998:11925 USPATFULL
TI DNA encoding human alpha 1 adrenergic receptors and uses thereof

IN Bard, Jonathan A., Wyckoff, NJ, United States
Forray, Carlos, Waldwick, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5714381 19980203
AI US 1995-468939 19950606 (8)
RLI Continuation of Ser. No. US 1994-334698, filed on 4 Nov 1994, now patented, Pat. No: US 5556753 which is a continuation of Ser. No. US 1992-952798, filed on 25 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Bugaisky, Gabriele E.
LREP White, John P.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 2580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 112 OF 138 USPATFULL
AB Apparatus and method for studying cellular processes comprise a vessel having a base including a layer comprising a scintillant substance and which is adapted for attachment and/or growth of cells. Cellular processes are examined by scintillation proximity assay using a reagent labelled with a radioisotope.
AN 97:81114 USPATFULL
TI Devices and methods for the measurement of cellular biochemical processes
IN Cook, Neil David, Peterston-Super-Ely, United Kingdom
PA Amersham International plc, Buckinghamshire, England (non-U.S. corporation)
PI US 5665562 19970909
WO 9426413 19941124
AI US 1995-373316 19950117 (8)
WO 1994-GB1040 19940516
19950117 PCT 371 date
19950117 PCT 102(e) date
PRAI EP 1993-303806 19930517
DT Utility
FS Granted
EXNAM Primary Examiner: Gitomer, Ralph J.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 113 OF 138 USPATFULL
AB This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters and methods of isolating these nucleic acid molecules. Further provided are vectors comprising the nucleic acid molecules as well as mammalian cells comprising such vectors, and antibodies directed to the GABA and taurine transporters. Nucleic acid probes useful for detecting nucleic acid molecules encoding GABA and taurine transporters are also provided. Antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a GABA or taurine transporter are further provided. Pharmaceutical compounds related to GABA and taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding a normal or a mutant GABA or taurine transporter are also provided. Further provided

are methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with GABA and taurine transporters.

AN 97:73495 USPATFULL

TI DNA encoding rat taurine transporter and uses thereof

IN Smith, Kelli E., Wayne, NJ, United States
Weinshank, Richard L., New York, NY, United States
Borden, Laurence A., Hackensack, NJ, United States
Hartig, Paul R., Princeton, NJ, United States

PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

PI US 5658786 19970819
WO 9318143 19930916

AI US 1994-295814 19941219 (8)
WO 1993-US1959 19930304
19941219 PCT 371 date
19941219 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1992-959936, filed on 13 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847742, filed on 4 Mar 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Walsh, Stephen; Assistant Examiner: Kaufman, Claire

LREP White, John P.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 39 Drawing Figure(s); 37 Drawing Page(s)

LN.CNT 3815

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 114 OF 138 USPATFULL

AB The nucleic acid coding for an .alpha.-acetolactate synthase from Lactococcus is provided, as well as vectors containing this nucleic acid and the use of these vectors for transforming microorganisms in which the production of .alpha.-acetolactate will be promoted, The nucleic acid comprises one or the other or both of a first segment corresponding to the ilvB gene (which encodes one subunit of .alpha.-acetolactate synthase of Lactococcus lactis subsp. lactis) and a second segment corresponding to the ilvN gene (which encodes a second subunit of .alpha.-acetolactate synthase of Lactococcus lactis subsp. lactis).

AN 97:56545 USPATFULL

TI Nucleic acid coding for an .alpha.-acetolactate synthase from lactococcus and its applications

IN Ehrlich, Stanislav, Paris, France
Godon, Jean-Jacques, Saint Pierre-de-Nemours, France
Renault, Pierre, Montigny-le-Bretonneux, France

PA Biotechnology and Biological Sciences Research Council, Great Britain (non-U.S. government)

PI US 5643779 19970701
WO 9408020 19940414

AI US 1995-403866 19950721 (8)
WO 1993-GB2012 19930927
19950721 PCT 371 date
19950721 PCT 102(e) date

PRAI FR 1992-11470 19920925

DT Utility

FS Granted

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Nashed, Nashaat T.

LREP Nixon, Hargrave, Devans & Doyle

CLMN Number of Claims: 17

ECL Exemplary Claim: 7

DRWN 10 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1804

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 115 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptor, an isolated protein which is a human 5-HT.sub.1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1F receptor, pharmaceutical compounds related to human 5-HT.sub.1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1F receptor.
AN 97:51902 USPATFULL
TI DNA encoding a human 5-HT.sub.1F receptor and uses thereof
IN Weinshank, Richard L., New York, NY, United States
Branchek, Theresa, Teaneck, NJ, United States
Hartig, Paul R., Princeton, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5639652 19970617
WO 9314201 19930722
AI US 1994-117006 19940822 (8)
WO 1993-US149 19930108
19940822 PCT 371 date
19940822 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-817920, filed on 8 Jan 1992, now patented, Pat. No. US 5360735, issued on 1 Nov 1994
DT Utility
FS Granted
EXNAM Primary Examiner: Walsh, Stephen; Assistant Examiner: Spector, Lorraine M.
LREP White, John P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 116 OF 138 USPATFULL
AB The presence invention contemplates chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor-donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore.
AN 96:94453 USPATFULL
TI Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfer system
IN Heller, Michael J., Encinitas, CA, United States
PA Nanogen, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5565322 19961015
WO 9309128 19930513
AI US 1994-232233 19940505 (8)
WO 1992-US9827 19921106
19940505 PCT 371 date
19940505 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1991-790262, filed on 7 Nov 1991,

now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Tran, Paul B.
LREP Lyon & Lyon
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 117 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor and an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, an isolated protein which is a human .alpha..sub.1a adrenergic receptor, an isolated protein which is .alpha..sub.1b adrenergic receptor and a isolated protein which is a human .alpha..sub.1c adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor, and vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, mammalian cells comprising such vectors, antibodies directed to the human .alpha..sub.1a adrenergic receptor, antibodies directed to the human .alpha..sub.1b adrenergic receptor, and antibodies directed to the human .alpha..sub.1c adrenergic receptor, nucleic acid probes useful for detecting nucleic acid encoding a human .alpha..sub.1a adrenergic receptor, nucleic acid probes useful for detecting nucleic acid encoding a human .alpha..sub.1b adrenergic receptor, and nucleic acid probes useful for detecting nucleic acid encoding a human .alpha..sub.1c adrenergic receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human .alpha..sub.1a adrenergic receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human .alpha..sub.1b adrenergic receptor, and antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human .alpha..sub.1c adrenergic receptor, pharmaceutical compounds related to the human .alpha..sub.1a adrenergic receptor, pharmaceutical compounds related to the human .alpha..sub.1b adrenergic receptors, and pharmaceutical compounds related to the human .alpha..sub.1c adrenergic receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human .alpha..sub.1a adrenergic receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian human .alpha..sub.1b adrenergic receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian human .alpha..sub.1c adrenergic receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha..sub.1a, .alpha..sub.1b and .alpha..sub.1c adrenergic receptors.
AN 96:85034 USPATFULL
TI DNA encoding human .alpha..sub.1 adrenegric receptors and uses thereof
IN Bard, Jonathan A., Wyckoff, NJ, United States
Forray, Carlos, Waldwick, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5556753 19960917
AI US 1994-334698 19941104 (8)
RLI Continuation of Ser. No. US 1992-952798, filed on 25 Sep 1992, now abandoned
DT Utility

FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Kim, Hyosuk
LREP White, John P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 2703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 118 OF 138 USPATFULL
AB Seven heterologous signal sequence are described for use with genes for insect controlling proteins, such that when the signal sequence and protein genes are inserted into an insect virus, that virus demonstrates an earlier onset of morbidity than a wild-type insect virus which lacks the gene for the insect controlling protein.
AN 96:75316 USPATFULL
TI Heterologous signal sequences for secretion of insect controlling proteins
IN Black, Bruce C., Yardley, PA, United States
Summers, Max D., Bryan, TX, United States4)
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5547871 19960820
AI US 1993-9265 19930125 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Hendricks, Keith D.
LREP Webster, Darryl L., Gordon, Alan M.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 2047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 119 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a human Y2 receptor, an isolated protein which is a human Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y2 receptor, pharmaceutical compounds related to human Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y2 receptor.
AN 96:72797 USPATFULL
TI DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
IN Gerald, Christophe, Ridgewood, NJ, United States
Walker, Mary W., Elmwood Park, NJ, United States
Branchek, Theresa, Teaneck, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5545549 19960813
AI US 1994-192288 19940203 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Walsh, Stephen G.; Assistant Examiner: Gucker, Stephen
LREP White, John P.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 120 OF 138 USPATFULL
AB The present invention contemplates chromophore-containing polynucleotides having at least two donor chromophores operatively linked to the polynucleotide by linker arms, such that the chromophores are positioned by linkage along the length of the polynucleotide at a donor-donor transfer distance, and at least one fluorescing acceptor chromophore operatively linked to the polynucleotide by a linker arm, such that the fluorescing acceptor chromophore is positioned by linkage at a donor-acceptor transfer distance from at least one of the donor chromophores, to form a photonic structure for collecting photonic energy and transferring the energy to an acceptor chromophore, and methods using the photonic structures.
AN 96:58106 USPATFULL
TI Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use
IN Heller, Michael J., Encinitas, CA, United States
PA Enterprise Partners II, L.P., La Jolla, CA, United States (U.S. corporation)
PI US 5532129 19960702
AI US 1994-250951 19940527 (8)
RLI Continuation of Ser. No. US 1991-790262, filed on 7 Nov 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Tran, Paul B.
LREP Lyon & Lyon
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 121 OF 138 USPATFULL
AB This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, an isolated protein which is a mammalian 5-HT.sub.4A receptor, an isolated protein which is a human 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4A receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4A receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4A receptor, pharmaceutical compounds related to the human 5-HT.sub.4A receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4A receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT.sub.4A receptor.
AN 95:108087 USPATFULL
TI DNA encoding 5-HT.sub.4A serotonin receptors
IN Gerald, Christophe, Ridgewood, NJ, United States
Hartig, Paul R., Kinnelon, NJ, United States
Branchek, Theresa A., Teaneck, NJ, United States
Weinshank, Richard L., New York, NY, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5472866 19951205

AI US 1992-996772 19921224 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Allen, Marianne P.
LREP White, John P.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1,14
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 122 OF 138 USPATFULL
AB This invention relates to nucleic acid sequences and methods useful for producing recombinant glucose-6-phosphate (G-6-Pase). In addition, the invention relates to specific mutations in the gene encoding human G-6-Pase and methods for detecting the mutations and thus diagnosing the genetic disease that causes glycogen storage disease type 1A.
AN 95:94808 USPATFULL
TI The catalytic moiety of the glucose-6-phosphatase system: the gene and protein and related mutations
IN Chou, Janice Y., Potomac, MD, United States
Lei, Ke-Jian, Bethesda, MD, United States
Shelly, Leslie L., Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5460942 19951024
AI US 1993-119773 19930910 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Pruty, Rebecca
LREP Townsend and Townsend Khourie and Crew
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 123 OF 138 USPATFULL
AB Novel classes of inhibitors which selectively inhibit the cellular transport of normally transported substances, specifically polyamines are taught which comprise (i) polymers of the transported substance or (ii) protein or polypeptide conjugates of the transported substance. These inhibitors may be used in vitro to assess the effect of the transported substance on cellular functions and in vivo for treating disease conditions involving transport of the particular substance, e.g., a polyamine.
AN 95:90332 USPATFULL
TI Polyamine-polyamine and polyamine-protein transport inhibitor conjugates and their use as pharmaceuticals and in research relating to polyamine transport
IN Aziz, Shewan M., Lexington, KY, United States
Gillespie, Mark N., Lexington, KY, United States
PA The University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)
PI US 5456908 19951010
AI US 1994-203629 19940301 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Burns, Doane, Swecker & Mathis
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 124 OF 138 USPATFULL
AB This invention provides an immunoenhancement or immunepotentiation therapy comprising administration of potassium, insulin, glucose and, optionally, thyroid, a cholinergic agent and bicarbonate. Therapeutic compositions comprising the above components in appropriate dosages are also provided.
AN 95:82121 USPATFULL
TI Pharmaceutical composition for immunoenhancement therapy
IN Hill, Albert F., 1755 Monaco Pkwy., Denver, CO, United States 80220
PI US 5449522 19950912
AI US 1993-111288 19930824 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Krass, Frederick; Assistant Examiner: Hulina, Amy
LREP Greenlee and Winner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 125 OF 138 USPATFULL
AB The present invention relates to methods for detecting the multidrug resistance phenotype in vivo and in vitro. The invention particularly relates to methods of diagnosing the multidrug resistance phenotype by imaging, particularly scintigraphic imaging, in solid tumors in vivo or in tumors and biopsies in vitro. The methods of the present invention allow the diagnosis of multidrug-resistant tumor and other multidrug-resistant phenotypes without invasive surgical methods.
AN 95:33903 USPATFULL
TI Evaluation of the multidrug resistance phenotype
IN Piwnica-Worms, David R., Wellesley, MA, United States
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5407653 19950418
AI US 1991-719714 19910626 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Lovering, Richard D.; Assistant Examiner: Chapman, Lara E.
LREP Sterne, Kessler, Goldstein & Fox
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1079
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 126 OF 138 USPATFULL
AB The present invention relates to methods for detecting the multidrug resistance phenotype in vivo and in vitro. The invention particularly relates to methods of diagnosing the multidrug resistance phenotype by imaging, particularly scintigraphic imaging, in solid tumors in vivo or in tumors and biopsies in vitro. The methods of the present invention allow the diagnosis of multidrug-resistant tumor and other multidrug-resistant phenotypes without invasive surgical methods. The present invention is also directed to methods of treating multidrug resistant tumors with novel agents that bind to P-glycoprotein. The novel compounds of the present invention are co-administered with a chemotherapeutic agent in order to enhance accumulation of the drug.
AN 95:29381 USPATFULL
TI Evaluation and treatment of the multidrug resistance phenotype
IN Piwnica-Worms, David R., Wellesley, MA, United States

PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5403574 19950404
AI US 1992-904363 19920626 (7)
RLI Continuation-in-part of Ser. No. US 1991-719714, filed on 26 Jun 1991
DT Utility
FS Granted
EXNAM Primary Examiner: Stoll, Robert L.; Assistant Examiner: Chapman, Lara E.
LREP Sterne, Kessler, Goldstein & Fox
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 127 OF 138 USPATFULL
AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of microorganisms, including Chromobacterium violaceum and Chlorella vulgaris.
AN 95:1343 USPATFULL
TI Processes to recover and reconcentrate gold from its ores
IN Kleid, Dennis G., foster City, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., San Francisco, CA, United States
PA Geobiotics, Inc., Hayward, CA, United States (U.S. corporation)
PI US 5378437 19950103
AI US 1992-920187 19920723 (7)
DCD 20091006
RLI Continuation of Ser. No. US 1990-617978, filed on 26 Nov 1990, now patented, Pat. No. US 5162105 which is a continuation-in-part of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven
LREP Lyon & Lyon
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1873
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 128 OF 138 USPATFULL
AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of microorganisms, including Chromobacterium violaceum and Chlorella vuloaris.
AN 94:17767 USPATFULL
TI Processes to recover and reconcentrate gold from its ores
IN Kleid, Dennis G., Foster, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., Oakland, CA, United States

PA Geobiotics, Inc., Hayward, CA, United States (U.S. corporation)
PI US 5290526 19940301
AI US 1992-907919 19920701 (7)
DCD 20091006
RLI Continuation of Ser. No. US 1991-677592, filed on 26 Mar 1991, now patented, Pat. No. US 5152969 which is a continuation of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven
LREP Lyon & Lyon
CLMN Number of Claims: 16
ECL Exemplary Claim: 6
DRWN No Drawings
LN.CNT 1439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 129 OF 138 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AB G. vaginalis is an important pathogen in the aetiology of bacterial vaginosis. Therefore, we investigated the influence of **transport systems** in isolation, a scoring system for Gram stains, and susceptibility to antimicrobial agents. The comparison between a simple (Transwab) and a sophisticated (Port-A-Cul) system showed no differences with regard to for instance Enterococcus faecalis or Escherichia coli; however, isolation of G. vaginalis, a fastidious microorganism, was significantly higher (alpha < 0.0001) in Port-A-Cul. There was a strong correlation (97.5%) using the scoring system indicating bacterial vaginosis and isolation of G. vaginalis. The minimal inhibitory concentrations (MIC) of metronidazole for 60 strains of G. vaginalis were higher than 32 mg/l, some strains showing heteroresistance. This phenomenon may be an explanation for treatment failures. Clindamycin and erythromycin were much more active, with MIC's between 0.016 and 0.19 mg/l, in-vitro development of resistance being slower for clindamycin than for erythromycin. Conclusions: (I) for isolation of G. vaginalis, a sophisticated transport system is mandatory; (II) a scoring system for Gram staining is helpful in diagnosis of bacterial vaginosis; (III) in patients with metronidazole treatment failures, clindamycin should be used.
AN 94:777533 SCISEARCH
GA The Genuine Article (R) Number: PU474
TI GARDNERELLA-VAGINALIS - TRANSPORT, MICROSCOPY, RESISTANCE TESTING
AU ALTRICHTER T; HEIZMANN W R (Reprint)
CS LENZHALDE 85, D-70192 STUTTGART, GERMANY (Reprint); INST VIROL INFEKTIOL & EPIEMIOL EV, STUTTGART, GERMANY
CYA GERMANY
SO GEBURTSHILFE UND FRAUENHEILKUNDE, (NOV 1994) Vol. 54, No. 11, pp. 606-611. ISSN: 0016-5751.
DT Article; Journal
FS CLIN
LA German
REC Reference Count: 45
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

L7 ANSWER 130 OF 138 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AB The genetic influences on the course of mycobacterial infections during epidemics and in endemic areas have always been suspected, but the precise nature of such genetic control and of the inherited mechanisms of susceptibility have been unknown. We have used methods of population genetics in the mouse to discover a single dominant autosomal gene (Bcg), which controls the susceptibility to various species of mycobacteria as well as to other intracellular parasites. The phenotypic expression of the Bcg gene has been defined as **nonspecific** macrophage activation for bactericidal function, resulting in the destruction of ingested intracellular parasites early following infection. Using recombinant

inbred strains of mice, we have mapped this gene to the centromeric part of chromosome 1 and we have created a high resolution linkage map and, subsequently, a physical map in the close vicinity of this locus. A 400 kb bacteriophage and cosmid contig assembled within the genomic interval overlapping Bcg contained six novel transcription units. RNA expression studies showed that one of these genes (designated Nramp for "natural resistance associated macrophage protein"), was expressed exclusively in macrophages. Nramp encodes an integral membrane protein that has structural homology with known prokaryotic and eukaryotic **transport systems**, suggesting a macrophage-specific membrane transport function. Susceptibility to infection (Bcg-s) in 27 Bcg-s and Bcg-r strains tested is associated with a Gly-105 to Asp-105 substitution within predicted transmembrane domain 2 of Nramp, making this gene a strong candidate for Bcg. The chromosomal segment in the vicinity of the Bcg gene has been conserved in the human genome (chromosome 2q). Linkage analysis between the phenotype of disease during a tuberculosis outbreak in an extended multisib Canadian Indian family and allelic variants of chromosome 2 has revealed a significant LOD score. This finding, together with the emerging information on almost total sequence homology between the murine and human Nramp genes suggests that this gene may be responsible for the phenotype of resistance or susceptibility to tuberculosis.

AN 1995:64028 BIOSIS
DN PREV199598078328
TI The Bcg gene story.
AU Skamene, Emil
CS Montreal General Hosp., 1650 Cedar Ave., Room B 7118, Montreal, PQ H3G 1A4 Canada
SO Immunobiology, (1994) Vol. 191, No. 4-5, pp. 451-460.
ISSN: 0171-2985.
DT General Review
LA English

L7 ANSWER 131 OF 138 USPATFULL
AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of microorganisms, including Chromobacterium violaceum and Chlorella vulgaris.
AN 92:96820 USPATFULL
TI Processes to recover and reconcentrate gold from its ores with microorganisms
IN Kleid, Dennis G., Foster City, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., San Francisco, CA, United States
PA Geobiotics, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5162105 19921110
AI US 1990-617978 19901126 (7)
DCD 20091006
RLI Continuation-in-part of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven
LREP Lyon & Lyon
CLMN Number of Claims: 32
ECL Exemplary Claim: 3
DRWN No Drawings
LN.CNT 1767

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 132 OF 138 USPATFULL

AB A variety of processes for recovering gold from gold ore are disclosed. Briefly, the methods include culturing at least one microorganism species capable of producing cyanide ion under conditions wherein the microorganism produces cyanide ion, thus forming a cyanide ion-containing culture; contacting the cyanide ion-containing culture with gold ore, causing production of gold ion-cyanide ion complexes and biosorption of said complexes to said cultures; and recovering gold from the culture. The invention may be practiced with a variety of microorganisms, including Chromobacterium violcaceum and Chlorella vulgaris.

AN 92:82551 USPATFULL

TI Processes to recover and reconcentrate gold from its ores with microorganisms

IN Kleid, Dennis G., Foster City, CA, United States
Kohr, William J., San Mateo, CA, United States
Thibodeau, Francis R., Palo Alto, CA, United States

PA Geobiotics, Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5152969 19921006

AI US 1991-677592 19910326 (7)

RLI Continuation of Ser. No. US 1989-441836, filed on 27 Nov 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lewis, Michael; Assistant Examiner: Bos, Steven

LREP Lyon & Lyon

CLMN Number of Claims: 11

ECL Exemplary Claim: 5

DRWN No Drawings

LN.CNT 1372

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 133 OF 138 MEDLINE

AB Bacterial periplasmic **transport systems** are complex, multicomponent permeases, present in Gram-negative **bacteria**. Many such permeases have been analyzed to various levels of detail. A generalized picture has emerged indicating that their overall structure consists of four proteins, one of which is a soluble periplasmic protein that binds the substrate and the other three are membrane bound. The liganded periplasmic protein interacts with the membrane components, which presumably form a complex, and which by a series of conformational changes allow the formation of an entry pathway for the substrate. The two extreme alternatives for such pathway involve either the formation of a **nonspecific** hydrophilic pore or the development of a ligand-binding site(s) on the membrane-bound complex. One of the membrane-bound components from each system constitutes a family of highly homologous proteins containing sequence domains characteristic of nucleotide-binding sites. Indeed, in several cases, they have been shown to bind ATP, which is thus postulated to be involved in the energy-coupling mechanism. Interestingly, eukaryotic proteins homologous to this family of proteins have been identified (mammalian mdr genes and Drosophila white locus), thus indicating that they perform a universal function, presumably related to energy coupling in membrane-related processes. The mechanism of energy coupling in periplasmic permeases is discussed.

AN 88153630 MEDLINE

DN 88153630 PubMed ID: 3279024

TI Structure and mechanism of bacterial periplasmic **transport systems**.

AU Ames G F

CS Department of Biochemistry, University of California, Berkeley 94720.

SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, (1988 Feb) 20 (1) 1-18. Ref:

86
Journal code: 7701859. ISSN: 0145-479X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 198804
ED Entered STN: 19900308
Last Updated on STN: 19900308
Entered Medline: 19880412

L7 ANSWER 134 OF 138 USPATFULL
AB Prodrugs are described whose structures have a oligopeptide chain which is substituted by a nucleophilic chemotherapeutic residue at the .alpha.-position. The products have increased cell membrane permeability and beneficial physico-chemical properties.
AN 84:60850 USPATFULL
TI Oligopeptide prodrugs
IN Gilvarg, Charles, Princeton, NJ, United States
Kingsbury, William D., King of Prussia, PA, United States
PA SmithKline Beckman Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 4479898 19841030
AI US 1984-584572 19840229 (6)
RLI Division of Ser. No. US 1983-507326, filed on 23 Jun 1983, now patented, Pat. No. US 4454065 which is a continuation-in-part of Ser. No. US 1982-379537, filed on 18 May 1982, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Edgerton, William H., Foggio, Richard D., Lourie, Alan D.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 135 OF 138 USPATFULL
AB Prodrugs are described whose structures have a oligopeptide chain which is substituted by a nucleophilic chemotherapeutic residue at the .alpha.-position. The products have increased cell membrane permeability and beneficial physico-chemical properties.
AN 84:32976 USPATFULL
TI Oligopeptide prodrugs
IN Gilvarg, Charles, Princeton, NJ, United States
Kingsbury, William D., King of Prussia, PA, United States
PA SmithKline Beckman Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 4454065 19840612
AI US 1983-507326 19830623 (6)
RLI Continuation-in-part of Ser. No. US 1982-379537, filed on 18 May 1982, now abandoned
PRAI ZA 1983-2844 19830422
DT Utility
FS Granted
EXNAM Primary Examiner: Phillips, Delbert R.
LREP Edgerton, William H., Foggio, Richard D., Lourie, Alan D.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 136 OF 138 USPATFULL

AB A novel combination and a method are disclosed for detecting and measuring a predetermined substance capable of being specifically bound. The combination comprises a novel adapter which eliminates contact of a light conducting and receiving probe with the sample. The novel combination comprises (1) a fiber optic colorimeter comprising a light source, a means for detecting and measuring light, and a probe containing a plurality of optic fibers including a first light conducting means for conducting light from the light source of the colorimeter to a test sample and a second light conducting means for conducting light from the test sample to the means for detecting and measuring light and (2) a microplate having one or more wells, each of which is adapted to contain a liquid test sample, for use in a predetermined colorimetric medical diagnostic test, wherein a reflective surface is disposed below the bottom of the well of said microplate, said well is adapted to accommodate the probe of said fiber optic colorimeter, and wherein said probe includes an attachment means joinable in a close-fitting engagement with an upper portion of each well in said microplate, the attachment means not engaging said liquid sample. The method of the invention is especially suitable for rapid manual examination of sample wells in microplates.

AN 80:64150 USPATFULL

TI Method and apparatus for specific binding substances

IN Linnecke, Carl B., Los Angeles, CA, United States
Wong, Daniel, Orange, CA, United States

PA Akzona Incorporated, Asheville, NC, United States (U.S. corporation)

PI US 4240751 19801223

AI US 1978-959386 19781109 (5)

DT Utility

FS Granted

EXNAM Primary Examiner: Evans, F. L.

LREP Falk, Robert H., Wendel, Charles A., Young, Francis W.

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1532

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 137 OF 138 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AB Proteins in the outer membrane of gram-negative **bacteria** serve as general porins or as receptors for specific nutrient **transport systems**. Many of these proteins are also used as receptors initiating the processes of colicin or phage binding and uptake. The functional activities of several outer membrane proteins in E. coli K-12 were followed after cessation or repression of their synthesis. Cessation of receptor synthesis was accomplished with a thermolabile suppressor activity acting on amber mutations in btuB (encoding the receptor for vitamin B12, the E colicins and phage BF23) and in fepA (encoding the receptor for ferric enterochelin and colicins B and D). After cessation of receptor synthesis, cells rapidly became insensitive to the colicins using that receptor. Treatment with spectinomycin or rifampin blocked appearance of insensitive cells and even increased susceptibility to colicin E1. Insensitivity to phage BF23 appeared only after a lag of about 1 division time, and the receptors remained functional for B12 uptake throughout. Therefore, possession of receptor is insufficient for colicin sensitivity, and some interaction of receptor with subsequent uptake components is indicated. Another example of physiological alteration of colicin sensitivity is the protection against many of the tonB-dependent colicins afforded by provision of Fe-supplying siderophores. The rate of acquisition of this **nonspecific** protection was consistent with the repression of receptor synthesis, rather than through direct and immediate effects on the tonB product or other components of colicin uptake or action.

AN 1980:281305 BIOSIS
DN BA70:73801
TI OUTER MEMBRANE DEPENDENT **TRANSPORT SYSTEMS** IN ESCHERICHIA-COLI EFFECT OF REPRESSION OR CESSATION OF COLICIN RECEPTOR SYNTHESIS ON COLICIN RECEPTOR ACTIVITIES.
AU KADNER R J; MCELHANEY G
CS DEP. MICROBIOL., UNIV. VA. SCH. MED., CHARLOTTESVILLE, VA. 22908, USA.
SO J BACTERIOL, (1980) 143 (1), 135-141.
CODEN: JOBAAY. ISSN: 0021-9193.
FS BA; OLD
LA English

L7 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2003 ACS
AB A re-view on the 3 structural models of membrane transport. Much evidence on the specific and **nonspecific** permeability barriers in the intact cells, and 3 types of transport, facilitated diffusion, un-coupled active transport of sugars and amino acids in **bacteria**, and coupled active transport of glucose in intestine, are reviewed. Also described are many examples of the substrate specificity of various membrane **transport systems**. A new anal. approach to such a specificity was divided into the following groups; (1) a binding protein model as a carrier, (2) an M-protein model, and (3) a phosphotransferase model as a sugar carrier. 187 references.
AN 1970:38817 CAPLUS
DN 72:38817
TI Biochemical approach to membrane transport
AU Anraku, Yasuhiro
CS Fac. Pharm. Sci., Tokyo Univ., Tokyo, Japan
SO Tanpakushitsu Kakusan Koso (1969), 14(8), 1-16
CODEN: TAKKAJ; ISSN: 0039-9450
DT Journal; General Review
LA Japanese

=>